var title_f28_24_29056="Para Hisian pacing lead";
var content_f28_24_29056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Para Hisian pacing lead",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient #6. Right anterior oblique (RAO) and left anterior oblique (LAO) fluoroscopic projections showing leads position during the \"ablate and pace\" procedure and Hisian pacing; 1 = quadripolar Hisian mapping catheter; 2 = screw-in bipolar lead positioned in close proximity to the His-bundle; 3 = bipolar passive fixation positioned in right ventricular apex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 2006; 47:1938. Copyright &copy;2006 American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29056=[""].join("\n");
var outline_f28_24_29056=null;
var title_f28_24_29057="Mitral stenosis as heard at the base";
var content_f28_24_29057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1170px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/66921/ms_base_conv.mp4?title=Mitral+stenosis+as+heard+at+the+base\" style=\"width:520px;height:414px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram and phonocardiogram of mitral stenosis as heard at the base. Following S2 (aortic and pulmonic valve closure) the is the opening of the stenotic mitral valve (snap) and a low pitched, faint mid diastolic murmur of mitral stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29057=[""].join("\n");
var outline_f28_24_29057=null;
var title_f28_24_29058="Patient information: Hemophilia (The Basics)";
var content_f28_24_29058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/10/42145\">",
"         Patient information: Taking care of bruises (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/36/42566\">",
"         Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hemophilia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hemophilia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H864641751\">",
"      <span class=\"h1\">",
"       What is hemophilia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hemophilia is a condition that keeps blood from clotting normally. If blood doesn&rsquo;t clot normally, people can bleed very easily or much more than normal. The bleeding can sometimes be life-threatening.",
"     </p>",
"     <p>",
"      People with hemophilia are missing certain proteins in the blood called &ldquo;clotting factors.&rdquo; Without these, the blood can&rsquo;t clot normally. There are 2 types of hemophilia, depending on which clotting factor is missing.",
"     </p>",
"     <p>",
"      Hemophilia is a life-long condition that people are born with. It is caused by an abnormal gene. Sometimes, parents pass this abnormal gene to their child. In some of these cases, parents might not know they have the abnormal gene, because they don&rsquo;t have any symptoms.",
"     </p>",
"     <p>",
"      Hemophilia can be mild or severe. There is no cure for the disease, but it can be managed with different treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641766\">",
"      <span class=\"h1\">",
"       What are the symptoms of hemophilia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on how mild or severe a person&rsquo;s hemophilia is. Some children start having symptoms from birth. For example, a baby boy might bleed much more than normal if he has a procedure to remove the skin that covers the tip of the penis (called &ldquo;circumcision&rdquo;). Other children, especially those with mild hemophilia, start having symptoms later on.",
"     </p>",
"     <p>",
"      People with mild hemophilia usually bleed more than normal after an injury, procedure, or surgery.",
"     </p>",
"     <p>",
"      People with severe hemophilia also bleed more than normal after an injury, procedure, or surgery. But they can also have bleeding that happens for no reason at all. This type of bleeding usually happens in a joint. The joints most often involved are the ankles, knees, and elbows. Blood in a joint can cause pain, swelling, stiffness, and trouble moving the joint. Over time, repeated bleeding in a joint can lead to long-term joint pain and damage.",
"     </p>",
"     <p>",
"      Symptoms can also happen from bleeding in other parts of the body. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood in a bowel movement",
"       </li>",
"       <li>",
"        Blood in the urine",
"       </li>",
"       <li>",
"        Belly pain (from bleeding into the belly wall)",
"       </li>",
"       <li>",
"        Bruises or collections of blood under the skin or in a muscle",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641781\">",
"      <span class=\"h1\">",
"       Is there a test for hemophilia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can check for hemophilia by doing different blood tests.",
"     </p>",
"     <p>",
"      Sometimes, babies are tested for hemophilia before they are born. Pregnant women with a family history of hemophilia can choose to test their unborn baby for the disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641798\">",
"      <span class=\"h1\">",
"       How is hemophilia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on how severe a person&rsquo;s hemophilia is and what activities he or she does. It also depends on whether he or she is going to have a procedure or surgery.",
"     </p>",
"     <p>",
"      The main treatment for hemophilia is called &ldquo;replacement therapy.&rdquo; This involves getting the clotting factor that the body is missing. There are different types of replacement clotting factors. Some are made from human blood, and others aren&rsquo;t. Replacement therapy goes into a vein. People can get this treatment in the hospital, or they can give it to themselves (or have someone else give it to them) at home.",
"     </p>",
"     <p>",
"      Replacement therapy is used in 2 ways:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        To treat a bleed when it happens",
"       </li>",
"       <li>",
"        On a regular basis, to prevent bleeding",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people with hemophilia take other types of medicines, too, that can help with clotting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641813\">",
"      <span class=\"h1\">",
"       What else should I know about replacement therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In the past, replacement therapy made from human blood sometimes had viruses in it. These viruses infected and caused serious problems in people with hemophilia. Today, replacement therapy is made in a safer way and does not contain these viruses.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641828\">",
"      <span class=\"h1\">",
"       What else can people with hemophilia do to avoid bleeding problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To avoid bleeding problems, people with hemophilia should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        See their doctor for regular visits, and get the vaccines he or she recommends",
"       </li>",
"       <li>",
"        Follow their doctor&rsquo;s instructions about treatment and which activities or sports to avoid (if any)",
"       </li>",
"       <li>",
"        Learn the signs and symptoms of bleeding, and how to treat it",
"       </li>",
"       <li>",
"        <strong>",
"         NOT",
"        </strong>",
"        take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or medicines called NSAIDs &ndash; Common NSAIDs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil, Motrin) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve, Naprosyn).",
"       </li>",
"       <li>",
"        Plan ahead for any procedures or surgery that could cause bleeding",
"       </li>",
"       <li>",
"        Take good care of their teeth and see their dentist for regular visits",
"       </li>",
"       <li>",
"        Take their replacement therapy with them when travelling",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child has hemophilia, you should let his or her caregivers, daycare, or school know. Teach them which symptoms to watch for, and how to treat a bleed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641843\">",
"      <span class=\"h1\">",
"       How can I learn more about hemophilia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To learn more, talk with your doctor or nurse. The Hemophilia Foundation also has a lot of information. Their website is",
"      <a class=\"external\" href=\"file://www.hemophilia.org/\">",
"       www.hemophilia.org",
"      </a>",
"      . Their toll-free phone number in the US is 1-800-424-2634.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H864641858\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"       Patient information: Taking care of bruises (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/24/29058?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83610 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29058=[""].join("\n");
var outline_f28_24_29058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641751\">",
"      What is hemophilia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641766\">",
"      What are the symptoms of hemophilia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641781\">",
"      Is there a test for hemophilia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641798\">",
"      How is hemophilia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641813\">",
"      What else should I know about replacement therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641828\">",
"      What else can people with hemophilia do to avoid bleeding problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641843\">",
"      How can I learn more about hemophilia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864641858\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=related_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29059="Aminolevulinic acid: Patient drug information";
var content_f28_24_29059=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aminolevulinic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     see \"Aminolevulinic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levulan&reg; Kerastick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levulan&reg; Kerastick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aminolevulinic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin where drug is used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with light therapy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will put on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10796 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29059=[""].join("\n");
var outline_f28_24_29059=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133386\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133387\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013778\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013777\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013782\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013783\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013785\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013780\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013781\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013786\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013787\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=related_link\">",
"      Aminolevulinic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29060="Muscle examination in the evaluation of weakness";
var content_f28_24_29060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Muscle examination in the evaluation of weakness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29060/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/24/29060/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient presenting with a complaint of &ldquo;weakness&rdquo; involves three steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distinguishing true muscle weakness from motor impairment due to fatigue, pain, or stiffness rather than loss of muscle power",
"     </li>",
"     <li>",
"      Localizing the site of the lesion within the neuromuscular system that is producing weakness",
"     </li>",
"     <li>",
"      Determining the cause of the lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The muscle examination is critical in the diagnostic evaluation of patients complaining of weakness or presenting with motor impairment. Together with the history and general physical examination, demonstrating the presence of true muscle weakness is the first step in this evaluation. Laboratory and electrophysiologic studies of nerves and muscles and muscle biopsy may then be required to complete the evaluation. Serial measurements of muscle strength and function are also necessary in the long-term follow-up of patients with neuromuscular disorders to determine response to treatment.",
"   </p>",
"   <p>",
"    This topic will describe a practical approach to the muscle examination that can be performed easily by the clinician in the hospital or office setting. The overall approach to patients with muscle weakness that specifically addresses the three issues mentioned above is discussed separately (",
"    <a class=\"graphic graphic_table graphicRef70008 \" href=\"UTD.htm?0/23/381\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67588 \" href=\"UTD.htm?10/47/11007\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MUSCLE EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient complaining of muscle weakness, the examiner should follow a systematic approach that includes inspection of muscle, palpation and percussion of muscle, manual muscle strength testing, and assessment of motor function. Joint examination and neurologic examination, including testing of the deep tendon reflexes and sensory testing, are important adjuncts to the muscle examination.",
"   </p>",
"   <p>",
"    More formalized quantitative and semiquantitative systems for measuring muscle strength and function have been developed for use in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29060/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In addition, more detailed description of testing of specific muscles is available in comprehensive manuals of muscle testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29060/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspection of muscle may provide important clues to the etiology of muscle weakness. The following observations are among the findings that may be seen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized atrophy may be seen as a result either of localized disuse secondary to joint disease or to joint pain (eg, quadriceps atrophy associated with chronic knee pain and disuse) or of lesions of the central or peripheral nervous systems (eg, thenar eminence atrophy due to compressive neuropathy of the median nerve or hemiatrophy and hemiparesis following a stroke).",
"     </li>",
"     <li>",
"      Widespread atrophy may occur in longstanding polymyositis unresponsive to therapy and in longstanding muscular dystrophies. The degree of generalized atrophy, as well as a general assessment of the size and musculature of the individual, should be noted as a basis for the subsequent formal testing of muscle strength.",
"     </li>",
"     <li>",
"      Enlargement of calf muscles due to pseudohypertrophy is characteristic of the Duchenne and Becker muscular dystrophies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fasciculations are due to spontaneous firing of motor units, and they may be observed in normal individuals, particularly with fatigue, or may be a sign of motor neuron disease. As an example, fasciculations of the tongue are seen in the bulbar form of amyotrophic lateral sclerosis.",
"     </li>",
"     <li>",
"      Ptosis may be a manifestation of myasthenia gravis, and the finding of an exaggerated kyphoscoliosis or lordosis may be a sign of spinal muscular weakness as seen in poliomyelitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Palpation and percussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helpful findings may be detected by palpation and percussion of muscle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with suspected myopathy, muscle tenderness suggests an infectious etiology or a metabolic myopathy such as McArdle&rsquo;s disease. In comparison, tenderness is an unusual finding in the idiopathic inflammatory myopathies such as polymyositis or dermatomyositis.",
"     </li>",
"     <li>",
"      Increased muscle tone or rigidity is present in Parkinson disease, a disorder in which weakness or decreased motor function may be an initial complaint. Increased tone also occurs in upper motor neuron lesions or in demyelinating diseases.",
"     </li>",
"     <li>",
"      Myotonia describes abnormal lack of relaxation after muscle contraction and is typical of myotonic dystrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"       \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myoedema is an unusual finding of localized &ldquo;mounding-up&rdquo; of the muscle where it has been tapped by a reflex hammer. It is a sign of severe hypothyroidism or cachexia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"       \"Hypothyroid myopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Manual muscle strength testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Medical Research Council&rsquo;s grading system for muscle strength is widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29060/abstract/7\">",
"     7",
"    </a>",
"    ]. The examiner assesses the patient&rsquo;s ability to move the muscle against resistance provided by the examiner who, through experience, has developed a sense of the expected range of normal. This will vary from patient to patient depending upon the underlying size and conditioning of the subject. The fully trained athlete obviously can be expected to perform differently from a small, sedentary, or deconditioned individual. The expected strength should also be adjusted for degree of atrophy in patients with wasting illnesses.",
"   </p>",
"   <p>",
"    The patient&rsquo;s effort is graded on a scale of 0 to 5:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      5 &mdash; Muscle contracts normally against full resistance.",
"     </li>",
"     <li>",
"      4 &mdash; Muscle strength is reduced, but muscle contraction can still move joint against resistance.",
"     </li>",
"     <li>",
"      3 &mdash; Muscle strength is further reduced such that the joint can be moved only against gravity with the examiner&rsquo;s resistance completely removed. As an example, the elbow can be moved from full extension to full flexion starting with the arm hanging down at the side.",
"     </li>",
"     <li>",
"      2 &mdash; Muscle can move only if the resistance of gravity is removed. As an example, the elbow can be fully flexed only if the arm is maintained in a horizontal plane.",
"     </li>",
"     <li>",
"      1 &mdash; Only a trace or flicker of movement is seen or felt in the muscle, or fasciculations are observed in the muscle.",
"     </li>",
"     <li>",
"      0 &mdash; No movement is observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This system was initially devised to evaluate trauma victims with rhabdomyolysis and is weighted toward the lower end of the range of strength. It is relatively less sensitive for the evaluation of mild weakness which is the usual range for patients with myopathies. To compensate for this, the addition of 4+ and 4- categories are added to the scale.",
"   </p>",
"   <p>",
"    This semiquantitative analysis of muscle strength relies on the full effort and cooperation of the patient. Thus, patients who are unable to follow instructions due to cognitive deficits or decreased level of consciousness cannot be tested. Decreased effort because of pain, fatigue, or malingering may be identified by &ldquo;give&rdquo; weakness in which there is initially a full effort followed by the abrupt loss of strength against resistance; this type of response does not occur in the truly weak individual. If intentionally decreased cooperation is suspected, observing the patient performing simple functional tasks such as sitting up from a supine position or toe or heel walking may reveal a discrepancy compared with the patient&rsquo;s performance on directed muscle strength testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Distribution of muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of weakness (localized [asymmetric] or generalized [symmetric]) is an important clue to diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef67588 \" href=\"UTD.htm?10/47/11007\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Localized weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized weakness is usually due to disease of the central or peripheral nervous system. Lesions of the motor cortex, spinal cord, spinal nerve root, and peripheral nerve have distinct distribution patterns. Common examples include isolated weakness of ankle dorsiflexion or &ldquo;foot drop&rdquo; resulting from mononeuritis multiplex due to vasculitis or a herniated disc that causes a lumbar radiculopathy; atrophy of the thenar eminence and weakness of hand grip due to median nerve compression or carpal tunnel syndrome; and quadriceps weakness due to a femoral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal weakness may also result from joint disease. Patients with joint damage from rheumatoid arthritis will develop weakness of the adjacent muscles due to disuse and atrophy or to joint deformity limiting full muscle function. Patients who have undergone hip replacement frequently develop focal weakness of the hip abductors that causes a characteristic lurching gait. It may be difficult to distinguish true muscle weakness from loss of function due to pain in individuals with joint disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Generalized weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized or symmetric muscle weakness may be proximal or distal. Proximal weakness involves the axial musculature, as well as the large muscles of the arms and thighs; it is the hallmark of most myopathies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deltoid strength can be tested by having the patient abduct his or her arms to 90&ordm; with elbows flexed and having the patient resist the downward pressure exerted by the examiner.",
"     </li>",
"     <li>",
"      Iliopsoas strength can be assessed by observing the patient sitting up from the supine position which should be easily accomplished without the use of the hands.",
"     </li>",
"     <li>",
"      Proximal lower extremity weakness can be detected by having the patient straight leg raise against resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distal strength is assessed by measuring grip strength and by testing wrist dorsiflexion and ankle dorsiflexion. Neuropathic causes of weakness should be excluded, as mononeuritis multiplex due to necrotizing vasculitis is often characterized by wrist or foot drop. The distribution of weakness in patients with an inflammatory myopathy is typically symmetric and proximal. Distal muscle weakness, if present, tends to be very mild and usually does not cause significant functional impairment. Muscle atrophy is generally not present in early cases, even in patients with severe weakness; however, it may be seen with advanced disease. This pattern is key to distinguishing polymyositis or dermatomyositis from other causes of diffuse muscle weakness, such as inclusion body myositis, in which both proximal and distal weakness occur and in which weakness is more likely to be asymmetric and is more likely to be accompanied by atrophy; muscular dystrophy, which has specific patterns of involvement depending upon the type; or motor neuron disease, which typically causes distal weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment of motor function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several simple functional tests can be performed in the office and may be tailored to the individual patient&rsquo;s clinical setting. These tests include observing the patient rising from a seated position without the use of the hands, climbing on and off an examination table, performing serial deep knee bends, elevating arms above the head, or lifting a weight with an extended arm to eye level. Observation of the patient during toe and heel walking is an easy way to assess dorsiflexion and plantar flexion ankle strength. The timed 50-foot walk can be easily repeated and followed at serial visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formal measurement of muscle strength using the Medical Research Council scale will demonstrate the presence of true muscle weakness. The muscle should be inspected and palpated to determine if atrophy, enlargement, tenderness, fasciculations, or other changes are present. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Manual muscle strength testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Muscle examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Inspection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Palpation and percussion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of the distribution of muscle weakness will help distinguish between neurologic and myopathic disorders. It is important to determine whether weakness is localized or generalized and whether it is largely proximal, distal, or both. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Distribution of muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confounding variables such as patient effort, degree of muscle atrophy, and presence of pain need to be considered. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Muscle examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29060/abstract/1\">",
"      Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29060/abstract/2\">",
"      Moxley RT 3rd. Evaluation of neuromuscular function in inflammatory myopathy. Rheum Dis Clin North Am 1994; 20:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29060/abstract/3\">",
"      Stoll T, Br&uuml;hlmann P, Stucki G, et al. Muscle strength assessment in polymyositis and dermatomyositis evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol 1995; 22:473.",
"     </a>",
"    </li>",
"    <li>",
"     Amundsen LR. Muscle Strength Testing, Churchill Livingstone, New York 1990.",
"    </li>",
"    <li>",
"     Gomez MR. The clinical examination in myology. In: Myology, Engel AG, Franzini-Armstrong C (Eds), McGraw-Hill, New York 1994. p.751.",
"    </li>",
"    <li>",
"     Hislop HJ, Montgomery J. Muscle Testing, 6th, WB Saunders, Philadelphia 1995.",
"    </li>",
"    <li>",
"     Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum no. 45. Her Majesty's Stationery Office, London, 1981.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5173 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29060=[""].join("\n");
var outline_f28_24_29060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MUSCLE EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Palpation and percussion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Manual muscle strength testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Distribution of muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Localized weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Generalized weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment of motor function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5173\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5173|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/47/11007\" title=\"algorithm 1\">",
"      Diagnostic approach to weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5173|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/23/381\" title=\"table 1\">",
"      Major causes of myopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29061="Valsartan and hydrochlorothiazide: Patient drug information";
var content_f28_24_29061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valsartan and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19575?source=see_link\">",
"     see \"Valsartan and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan HCT&reg;;",
"     </li>",
"     <li>",
"      Sandoz Valsartan HCT;",
"     </li>",
"     <li>",
"      Teva-Valsartan HCTZ;",
"     </li>",
"     <li>",
"      Valsartan-HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valsartan, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11138 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29061=[""].join("\n");
var outline_f28_24_29061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233260\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233261\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022145\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022147\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022146\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022151\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022152\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022154\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022149\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022150\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022155\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022156\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19575?source=related_link\">",
"      Valsartan and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29062="Periorificial dermatitis - periocular";
var content_f28_24_29062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periorificial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present in the periorbital region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29062=[""].join("\n");
var outline_f28_24_29062=null;
var title_f28_24_29063="ECG bidirectional VT";
var content_f28_24_29063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1055px;\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing bidirectional ventricular tachycardia (VT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythm strip showing bidirectional ventricular tachycardia (VT) which may be a manifestation of digoxin toxicity. This rare, life-threatening tachyarrhythmia is characterized by beat-to-beat changes in the polarity of consecutive premature ventricular complexes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29063=[""].join("\n");
var outline_f28_24_29063=null;
var title_f28_24_29064="Evaluation of dizziness in children and adolescents";
var content_f28_24_29064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of dizziness in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Theresa Walls, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29064/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/24/29064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26102360\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a common pediatric complaint in ambulatory settings, dizziness is a vague term that can describe many conditions, including lightheadedness (presyncope), anxiety, intoxication, ataxia, visual disturbance, hyperventilation, weakness, depression, and true vertigo. Young children may not be able to describe their symptoms well, making their evaluation challenging. However, a thorough history and physical examination can establish a diagnosis in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3781563\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizziness describes a disturbed sense of relationship to space [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/1\">",
"     1",
"    </a>",
"    ]. True vertigo refers to the perception that the patient is rotating relative to the environment (subjective vertigo) or that the environment is rotating relative to the patient (objective vertigo) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/2\">",
"     2",
"    </a>",
"    ]. It results from a disturbance somewhere in the vestibular system, which has both peripheral and central nervous system components. Pseudovertigo describes complaints of dizziness without any rotary component. &nbsp;",
"   </p>",
"   <p>",
"    The semicircular canals and vestibule (together known as the labyrinth) make up the peripheral vestibular system and are located within the inner ear, adjacent to the cochlea in the petrous portion of the temporal bone (",
"    <a class=\"graphic graphic_figure graphicRef63141 \" href=\"UTD.htm?32/32/33285\">",
"     figure 1",
"    </a>",
"    ). These organs send impulses to the central components of the vestibular system, located in the brainstem, cerebellum, and cortex, via the eighth cranial nerve (",
"    <a class=\"graphic graphic_figure graphicRef55465 \" href=\"UTD.htm?4/63/5110\">",
"     figure 2",
"    </a>",
"    ). Efferent impulses travel through the vestibulospinal tract to the peripheral muscles and also within the medial longitudinal fasciculus to cranial nerves III, IV, and VI. A disturbance anywhere in the vestibular system may cause patients to have vertigo and associated signs and symptoms such as hearing loss, perceptual changes in vision (eg, blurry vision), and nystagmus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102367\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may use \"dizziness\" to describe a wide range of symptoms; it is useful to divide diagnoses into those that represent true vertigo with a sensation of spinning from pseudovertigo (",
"    <a class=\"graphic graphic_table graphicRef51313 \" href=\"UTD.htm?4/53/4957\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H3781563\">",
"     'Definition'",
"    </a>",
"    above). The most common causes of true vertigo in children are otitis media, migraine headache, and benign paroxysmal vertigo of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Head injury and central nervous system infection are the most frequent life-threatening etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102374\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102382\">",
"    <span class=\"h3\">",
"     Head trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head injuries from falls, sports, and motor vehicle accidents are common among children. A fracture of the temporal bone may damage the labyrinth and classically presents with dizziness, hearing loss, and hemotympanum. A direct blow to the temporoparietal or parietooccipital regions can cause a vestibular concussion, which produces nausea, vertigo, and nystagmus in addition to the classic symptoms of a concussion. A whiplash (hyperflexion and extension) injury may injure the basilar artery, which partially supplies the labyrinth, causing spasm and producing vestibular symptoms. Blunt or penetrating trauma to the middle ear may disrupt the oval window and cause a perilymph fistula. Loud sounds or pneumatic otoscopy cause true vertigo in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H20#H20\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Post-traumatic vertigo'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of middle ear trauma\", section on 'Adjacent structures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102389\">",
"    <span class=\"h3\">",
"     Central nervous system infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral and bacterial infections of the central nervous system may affect the vestibular system and cause symptoms of dizziness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertigo. Patients will usually present with additional signs and symptoms of infection such as fever, headache, neck stiffness, or mental status changes. Several retrospective reviews found no cases of meningitis or encephalitis among children presenting to outpatient clinics with dizziness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertigo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. However, any child with fever or mental status changes deserves careful evaluation to rule out these potentially serious conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102396\">",
"    <span class=\"h3\">",
"     Intracranial tumor or abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although vertigo is a rare presenting sign in patients with a space occupying brain lesion, any mass in or around the fourth ventricle or central vestibular system may cause dizziness, vertigo, or nystagmus due to compression, displacement, or localized inflammation of the brain. The symptoms typically worsen with changes in head position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102403\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strokes in children most commonly present with hemiplegia or altered mental status (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H17#H17\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Clinical presentation'",
"    </a>",
"    ). However, symptoms of dizziness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vertigo may occur if the defect occurs in the area of the basilar artery, which partially supplies the labyrinth, the vestibular nuclei of the brainstem, or in vessels that supply any of the vestibular centers in the cortex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102410\">",
"    <span class=\"h3\">",
"     Drug overdose and other poisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of certain recreational drugs may cause vertigo and nystagmus, including barbiturates, ethanol,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , and phencyclidine. Pseudovertigo may occur in patients with poisoning due to benzodiazepines, carbon monoxide, typical antipsychotic medications, and cyclic antidepressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102417\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102425\">",
"    <span class=\"h3\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otitis media is the most common cause of vestibular disturbances in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/7\">",
"     7",
"    </a>",
"    ]. Between 60 and 80 percent of infants have at least one episode of AOM by one year of age, and 80 to 90 percent by two to three years. An acute episode of otitis media (serous or suppurative) can irritate the vestibular system and cause dizziness, vertigo,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hearing loss. Complications of otitis media that may also cause vertigo include mastoiditis, an infection of the mastoid air cells, and cholesteatoma, an abnormal collection of keratin on the tympanic membrane caused by repeated episodes of otitis media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Symptoms and signs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link&amp;anchor=H8#H8\">",
"     \"Cholesteatoma in children\", section on 'Natural history and complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102432\">",
"    <span class=\"h3\">",
"     Migraine syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migrainous vertigo is a term used to describe episodic vertigo in patients with a history of migraines or with other clinical features of migraine. Unlike adults, who generally present with headache, children may present with other manifestations of migraine such as vertigo and frequently have no associated headache. In addition, up to 19 percent of children with classic migraine have vertiginous symptoms during their aura. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link&amp;anchor=H2#H2\">",
"     \"Migrainous vertigo\", section on 'Proposed criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link&amp;anchor=H7#H7\">",
"     \"Migrainous vertigo\", section on 'Clinical and epidemiologic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basilar artery migraines, which are most common before the age of 20 years, present with two or more basilar-type aura symptoms including vertigo. Symptoms resolve within two hours and are usually followed by a throbbing headache (",
"    <a class=\"graphic graphic_table graphicRef73674 \" href=\"UTD.htm?36/28/37323\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link&amp;anchor=H3#H3\">",
"     \"Basilar-type migraine\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102439\">",
"    <span class=\"h3\">",
"     Benign paroxysmal vertigo of childhood (BPVC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal vertigo (BPV) is a disorder of early childhood manifested by recurrent episodes of brief disequilibrium. During the attacks, the child appears frightened and off balance, often reaching out to steady him or herself. The events may be associated with nystagmus, diaphoresis, nausea, and vomiting. Older children will grab nearby persons or furniture for support to prevent falling and may complain of vertigo or dizziness. Episodes usually last less than a minute and are not associated with an altered consciousness. They usually recur in clusters, occurring daily for several days in a row, then remitting for several weeks, and recurring again. A family history of migraine headaches is frequently present. The neurologic examination is normal between episodes. The disorder typically remits spontaneously by five years of age. Many patients subsequently develop typical migraine headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonepileptic paroxysmal disorders in children\", section on 'Benign paroxysmal vertigo'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Unlike other causes of nystagmus, patients with BPVC have normal eye and neurologic examinations between episodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=see_link\">",
"     \"Pendular nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363944\">",
"    <span class=\"h3\">",
"     Adverse effects of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of medications list dizziness as a possible side effect. Several affect the labyrinth and may cause true vertigo, including aminoglycosides,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43334?source=see_link\">",
"     minocycline",
"    </a>",
"    , and salicylates. Medications known to induce nystagmus include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    , MAO inhibitors,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/12/19655?source=see_link\">",
"     quinine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102453\">",
"    <span class=\"h3\">",
"     Motion sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion sickness is caused by a mismatch between visual, vestibular, and somatosensory cues provided to the brain. As an example, if the visual system indicates that a person is stationary (eg, viewing the interior of a cabin on a ship), but the vestibular system senses ongoing head movements (eg, due to motion of the ship), the vestibular and visual cues conflict and engender symptoms of motion sickness. Furthermore, if the semicircular canals and otolith organs produce sensory cues that are incongruous, motion sickness can be evoked that is independent of vision. Common symptoms include pallor, diaphoresis, dizziness, nausea, and vomiting, and usually occur during travel in a boat, car, or airplane. It is much more common in children who have migraines compared to those without. True vertigo is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=see_link&amp;anchor=H2#H2\">",
"     \"Motion sickness\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=see_link&amp;anchor=H7#H7\">",
"     \"Motion sickness\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102460\">",
"    <span class=\"h3\">",
"     Paroxysmal torticollis of infancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal torticollis is a benign, self-limited condition characterized by recurrent episodes of head tilt often accompanied by vomiting, pallor, irritability, ataxia, or drowsiness that usually presents in the first few months of life. The periodic episodes of torticollis can randomly alternate from side to side. The individual attacks typically last for hours, but occasionally last for days. The episodes occur less frequently as the child gets older and disappear in most cases by five years of age. The pathogenesis of benign paroxysmal torticollis has not been determined. It is considered to be a \"migraine equivalent\" disorder. Some patients go on to develop migraine headaches or benign paroxysmal vertigo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link&amp;anchor=H7#H7\">",
"     \"Acquired torticollis in children\", section on 'Benign paroxysmal torticollis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paroxysmal torticollis of infancy has findings that are similar to spasmus nutans; however, unlike patients with paroxysmal torticollis, children with spasmus nutans typically have head nodding and strabismus with amblyopia. In addition, patients with spasmus nutans do not go on to develop migraine headaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=see_link&amp;anchor=H9#H9\">",
"     \"Pendular nystagmus\", section on 'Spasmus nutans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3781615\">",
"    <span class=\"h3\">",
"     Pseudovertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions may produce subjective feelings of dizziness without a sensation of spinning (",
"    <a class=\"graphic graphic_table graphicRef51313 \" href=\"UTD.htm?4/53/4957\">",
"     table 1",
"    </a>",
"    ). Many of these illnesses cause reduced blood flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compromised delivery of oxygen or glucose to the brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102467\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102475\">",
"    <span class=\"h3\">",
"     Vestibular neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular neuritis, also known as vestibular neuronitis or labyrinthitis, represents an acute, spontaneous, peripheral vestibular ailment, characterized by the rapid onset of severe vertigo with nausea, vomiting, and gait instability. Vestibular neuritis is a common cause of vertigo in adults, but is rare in children. Patients prefer to lie still with the affected ear facing up. There is no associated hearing loss. It is thought to be due to a postinfectious inflammation or viral infection of the vestibular nerve, with mumps, measles, Epstein-Barr virus, and herpesvirus being known pathogens. However, a history of a recent viral infection is present in less than half of patients. Symptoms may last from weeks to months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link&amp;anchor=H2#H2\">",
"     \"Vestibular neuritis\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link&amp;anchor=H3#H3\">",
"     \"Vestibular neuritis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Labyrinthitis, a specific type of vestibular neuritis, presents with the sudden onset of hearing loss and vertigo. It is caused by a viral or bacterial infection of the labyrinth and may occur alone or as a complication of otitis media or meningitis. Hearing loss may be permanent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102482\">",
"    <span class=\"h3\">",
"     Benign paroxysmal positional vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal positional vertigo (BPPV) is rare in children, but has been reported in the literature in a patient as young as three years old [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients typically complain of vertigo with changes in head position, especially upon waking in the morning and sitting up in bed. Episodes usually last less than one minute. The symptoms can be elicited by the Dix-Hallpike (or Nylen-Barany) maneuver, in which the patient's neck is extended and turned to one side before he or she is placed supine rapidly (",
"    <a class=\"graphic graphic_figure graphicRef52232 \" href=\"UTD.htm?34/32/35330\">",
"     figure 3",
"    </a>",
"    ). In patients with BPPV, nystagmus should occur within 30 seconds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link&amp;anchor=H5#H5\">",
"     \"Benign paroxysmal positional vertigo\", section on 'Examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=see_link&amp;anchor=H11970404#H11970404\">",
"     \"Benign paroxysmal positional vertigo\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102489\">",
"    <span class=\"h3\">",
"     Meniere disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Meniere disease consist of fullness in the affected ear, tinnitus, vertigo, and fluctuating unilateral sensorineural hearing loss. Episodes may be accompanied by autonomic symptoms such as pallor, nausea, and vomiting. Meniere disease is associated with endolymphatic hydrops with distortion and distention of the membranous, endolymph-containing portions of the labyrinthine system. Meniere disease can begin at any age but patients typically present with symptoms between the ages of 20 and 40. Meniere syndrome in children is most often associated with congenital malformations of the inner ear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link&amp;anchor=H4#H4\">",
"     \"Meniere disease\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=see_link&amp;anchor=H3#H3\">",
"     \"Meniere disease\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26102524\">",
"     'Congenital defects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102496\">",
"    <span class=\"h3\">",
"     Perilymphatic fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;A perilymphatic fistula is an abnormal connection between the inner and middle ear. It may be congenital, causing permanent sensorineural hearing loss, or acquired. Acquired causes include barotrauma (from diving, descending in an airplane that is not well pressurized, sneezing, coughing, or any sudden change in pressure in the middle ear), head injury, middle ear trauma, and middle ear infection. The diagnosis is suggested by sudden or fluctuating hearing loss accompanied by dizziness or vertigo. Symptoms should worsen with changes in middle ear pressure and may be elicited by pneumatic otoscopy, having the patient Valsalva (positive Hennebert's sign), or Tullio phenomenon (vertigo and nystagmus in response to a loud sound). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of scuba diving\", section on 'Ear barotrauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of middle ear trauma\", section on 'Adjacent structures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102503\">",
"    <span class=\"h3\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures, while common in children, do not often present with true vertigo. Two kinds of seizures involve the vestibular system. Vestibular seizures are characterized by the sudden onset of vertigo followed by a loss of consciousness or postictal state. Vestibulogenic seizures are seizures induced by stimulating the vestibular system via sudden rotation or caloric testing. The EEG will be abnormal in both cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102510\">",
"    <span class=\"h3\">",
"     Ramsay Hunt syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ramsay Hunt syndrome (Herpes zoster oticus) arises from Varicella-zoster reactivation with Herpes zoster infection of the ear canal. Clinical manifestations include auricular and auditory canal vesicles, facial paralysis, and ear pain. Vertigo is also frequently reported and occurs when the herpesvirus affects the eighth cranial nerve, causing symptoms of vestibular neuritis. (See",
"    <a class=\"local\" href=\"#H26102475\">",
"     'Vestibular neuritis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Ramsay Hunt syndrome (Herpes zoster oticus)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102517\">",
"    <span class=\"h3\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis is most commonly seen in young women and is rare in children. Vertigo is a reported symptom in 30 to 50 percent of patients with MS. It is commonly associated with symptoms reflecting dysfunction of adjacent cranial nerves such as hyper or hypoacusis, facial numbness, and diplopia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Vertigo'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102524\">",
"    <span class=\"h3\">",
"     Congenital defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of rare congenital malformations of the cochlea and central or peripheral vestibular system cause vertigo and include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29064/abstract/9\">",
"     9",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital anomalies of the ear\", section on 'Inner ear malformations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mondini anomaly with cochlear growth arrest during embryologic development at less than one complete turn (instead of 2.75 turns in the normally developed inner ear).",
"     </li>",
"     <li>",
"      Michel anomaly in which the labyrinth is absent or reduced to a single cystic cavity.",
"     </li>",
"     <li>",
"      The large vestibular aqueduct syndrome, which is associated with sensorineural or mixed hearing loss and vertigo.",
"     </li>",
"     <li>",
"      Scheibe deformity with membranous cochleosaccular degeneration of the inner ear with hearing loss and vertigo.",
"     </li>",
"     <li>",
"      Usher syndrome, an autosomal recessive syndrome with hearing loss, vertigo, and progressive vision loss due to retinitis pigmentosa.",
"     </li>",
"     <li>",
"      Joubert syndrome, an autosomal recessive syndrome with underdevelopment of the cerebellar vermis, ataxia, dysmetria, intellectual disability, oculomotor apraxia, and seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102531\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102539\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating children with dizziness, the clinician first must differentiate between pseudovertigo and true vertigo (see",
"    <a class=\"local\" href=\"#H3781563\">",
"     'Definition'",
"    </a>",
"    above). The essential element of true vertigo is a sensation of spinning. However, in young children who cannot describe this sensation, a history of ataxia, vomiting, irritability, desire to lay still, or eye twitching (nystagmus) may be present.",
"   </p>",
"   <p>",
"    Other key historical elements include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preceding head or middle ear trauma. (See",
"      <a class=\"local\" href=\"#H26102382\">",
"       'Head trauma'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Fever &ndash; A history of fever points toward infection of the ear or central nervous system. (See",
"      <a class=\"local\" href=\"#H26102389\">",
"       'Central nervous system infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26102425\">",
"       'Otitis media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Altered mental status &ndash; Mental status changes may occur with meningitis, encephalitis, intracranial abscess, seizures (postictal state), stroke, tumor, or ingestion.",
"     </li>",
"     <li>",
"      Possible poisoning or use of recreational drugs &ndash; Any medications in the household should be noted as they could be possible ingestants. (See",
"      <a class=\"local\" href=\"#H26102410\">",
"       'Drug overdose and other poisons'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ataxia &ndash; Ataxia suggests a posterior fossa process, such as a central nervous system tumor, infection, or inflammation. (See",
"      <a class=\"local\" href=\"#H26102389\">",
"       'Central nervous system infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26102396\">",
"       'Intracranial tumor or abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vomiting &ndash; Emesis commonly accompanies vertigo from peripheral causes. However, vomiting associated with meningismus, ataxia, or other cranial nerve abnormalities (eg, facial weakness, visual disturbance) suggests increased intracranial pressure associated with a central nervous system tumor, abscess, or infection. (See",
"      <a class=\"local\" href=\"#H26102389\">",
"       'Central nervous system infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26102396\">",
"       'Intracranial tumor or abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hearing loss &ndash; Decreased hearing may occur with temporal bone fracture, otitis media, labyrinthitis, Meniere disease, perilymphatic fistula, and some medications.",
"     </li>",
"     <li>",
"      Recent upper respiratory tract infection &ndash; Viral infection may precede vestibular neuritis or otitis media. (See",
"      <a class=\"local\" href=\"#H26102475\">",
"       'Vestibular neuritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26102425\">",
"       'Otitis media'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent episodes of otitis media (see",
"      <a class=\"local\" href=\"#H26102425\">",
"       'Otitis media'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Current medications (see",
"      <a class=\"local\" href=\"#H363944\">",
"       'Adverse effects of medications'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Time course of symptoms onset &ndash; The onset of vertigo is usually acute with trauma, stroke, meningitis, encephalitis, otitis media, mastoiditis, cholesteatoma, vestibular neuronitis, labyrinthitis, Ramsay Hunt syndrome, multiple sclerosis, and ingestion or drug use. (See",
"      <a class=\"local\" href=\"#H26102367\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence of vertigo &ndash; A history of recurrent episodes of vertigo suggests migraine headache or any if its variants (eg, benign paroxysmal vertigo of childhood, motion sickness, paroxysmal torticollis of infancy), seizures, perilymphatic fistula, Meniere disease, or benign paroxysmal positional vertigo. (See",
"      <a class=\"local\" href=\"#H26102367\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recent travel (see",
"      <a class=\"local\" href=\"#H26102453\">",
"       'Motion sickness'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A past medical history of recurrent headaches in the patient or family members (see",
"      <a class=\"local\" href=\"#H26102432\">",
"       'Migraine syndromes'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age of the patient is also helpful in narrowing the differential diagnosis of vertigo. Children under five years of age typically have otitis media, benign paroxysmal vertigo, or rarely, paroxysmal torticollis of infancy. Children under 10 years of age rarely have Meniere disease, multiple sclerosis, or benign paroxysmal positional vertigo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102546\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to performing a complete physical examination, the clinician should pay special attention to vital signs, ear findings, nystagmus, other vestibular signs, and any neurologic abnormalities.",
"   </p>",
"   <p>",
"    Patients with vertigo following significant head injury warrant appropriate trauma assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link&amp;anchor=H8#H8\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Acute evaluation and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial approach to severe traumatic brain injury in children\", section on 'Physical examination'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Children with fever and signs of meningitis or encephalitis (eg, meningismus, altered mental status) may present with respiratory or hemodynamic instability and may require airway management",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of septic shock, and warrant empiric antibiotic or antiviral therapy (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef65304 \" href=\"UTD.htm?14/27/14770\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=see_link&amp;anchor=H8#H8\">",
"     \"Viral meningitis: Management, prognosis, and prevention in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364247\">",
"    <span class=\"h3\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever suggests an infectious cause of vertigo. Hypertension with tachycardia or bradycardia implies increased intracranial pressure due to head trauma or a space-occupying tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364255\">",
"    <span class=\"h3\">",
"     Ear examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings suggest specific etiologies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vesicles on the auricle or in the auditory canal (Ramsay Hunt syndrome)",
"     </li>",
"     <li>",
"      Tympanic membrane erythema, bulging, or decreased mobility in association with middle ear effusion (otitis media)",
"     </li>",
"     <li>",
"      Hemotympanum, otorrhea, tympanic membrane perforation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disruption of the ossicles (temporal bone fracture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      middle ear injury)",
"     </li>",
"     <li>",
"      Swelling, erythema, and tenderness of the mastoid (mastoiditis)",
"     </li>",
"     <li>",
"      Vertigo and nystagmus following a loud noise (Tullio phenomenon) or with pneumatic otoscopy of an intact tympanic membrane (perilymphatic fistula)",
"     </li>",
"     <li>",
"      Hearing loss (otitis media, mastoiditis, middle ear trauma, labyrinthitis). A discussion of hearing tests that can be simply performed in the ambulatory setting is provided separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H20#H20\">",
"       \"Approach to the patient with vertigo\", section on 'Office hearing tests'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Deep retraction pocket (",
"      <a class=\"graphic graphic_picture graphicRef54514 \" href=\"UTD.htm?41/35/42550\">",
"       picture 1",
"      </a>",
"      ) or white mass behind the tympanic membrane (",
"      <a class=\"graphic graphic_picture graphicRef76079 \" href=\"UTD.htm?6/8/6272\">",
"       picture 2",
"      </a>",
"      ) (cholesteatoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364388\">",
"    <span class=\"h3\">",
"     Nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular nystagmus is the most common physical manifestation of vertigo. Features of the nystagmus: its type (horizontal, torsional, vertical), its tendency to suppress with visual fixation, and whether or not its direction alters with gaze position can suggest a central versus peripheral localization (",
"    <a class=\"graphic graphic_table graphicRef76359 \" href=\"UTD.htm?29/33/30235\">",
"     table 4",
"    </a>",
"    ). Evaluation of nystagmus is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the patient with vertigo\", section on 'Nystagmus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364512\">",
"    <span class=\"h3\">",
"     Other vestibular signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caloric testing is performed by infusing warm or cold water into the ear. Otoscopy should be performed first to ensure that cerumen is not obstructing the flow of water to the tympanic membrane and to verify that there is no tympanic membrane perforation. The head of the patient should be tilted at 30 degrees for optimal stimulation of the semicircular canals. When warm water at 44&ordm;C is infused into an ear, the normal response is nystagmus with the fast component toward the infused ear. The opposite response occurs when cold water at 30&ordm;C is infused; the normal response is nystagmus with the fast component away from the cold water-infused ear. The volume of water can be increased if no response occurs with the initial attempt. Lack of a response to warm or cold water on one side suggests disease on that side, usually in peripheral lesions. Central vestibular disorders may also cause caloric hyposensitivity, especially if they involve the vestibular root entry in the medulla. This test can cause significant distress, including nausea and vomiting in patients who are awake.",
"   </p>",
"   <p>",
"    Other tests of vestibular function include the Dix-Hallpike maneuver (",
"    <a class=\"graphic graphic_figure graphicRef52232 \" href=\"UTD.htm?34/32/35330\">",
"     figure 3",
"    </a>",
"    ), which tests for benign paroxysmal positional vertigo (rare in children), tests of static vestibular imbalance (eg, skew deviation, ocular tilt reaction, tilt of the subjective visual vertical), and tests of dynamic vestibular imbalance (eg, head thrust test, head shaking visual acuity, head shaking nystagmus). Evaluation of static and dynamic vestibular function can assist in differentiating vertigo from central versus peripheral nervous system causes, but requires patient cooperation. Instructions on the performance and interpretation of these tests are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the patient with vertigo\", section on 'Dix-Hallpike maneuver'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the patient with vertigo\", section on 'Other vestibular signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364263\">",
"    <span class=\"h3\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered mental status is seen in patients with central nervous system infection, increased intracranial pressure, or poisoning. A careful neurologic examination should be performed since the presence of additional neurologic abnormalities also strongly suggests the presence of a central lesion. A search should be made for cranial nerve abnormalities, motor or sensory changes, dysmetria, or abnormal reflexes. Unilateral peripheral vestibular disorders (eg, otitis media, benign paroxysmal vertigo) generally cause patients to lean or fall toward the side of the lesion. Children may be uncomfortable and reluctant to move because of their vertigo, but they are still able to walk. Romberg testing will cause the patients to fall or tilt to one side. Patients with an acute cerebellar lesion (eg, posterior fossa tumor) are often unable to walk without falling. The direction of tilting or falling with Romberg testing may vary.",
"   </p>",
"   <p>",
"    While the ability to walk and the direction of falling may provide useful clues to the origin of vertigo, in practice, it may be difficult to persuade a patient with severe vertigo to attempt to walk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the patient with vertigo\", section on 'Other neurologic signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102553\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of true vertigo, additional evaluation is dictated by the history and physical examination. Neuroimaging is indicated for patients with a history of trauma (computed tomography (CT) of the head with temporal bone windows) or patients with evidence of central vestibular abnormalities, altered mental status, or associated focal neurologic findings (magnetic resonance imaging (MRI) of the brain or head CT). Once increased intracranial pressure is excluded by physical examination or neuroimaging, lumbar puncture should be performed in patients with suspected meningitis, encephalitis, or multiple sclerosis. In patients with a suspicion of seizures, an electroencephalogram should be arranged.",
"   </p>",
"   <p>",
"    Other specialized vestibular testing (eg, electronystagmography, rotary chair testing, posturography, and audiometry) is indicated when central versus peripheral vertigo cannot be established or when vertigo is prolonged or incapacitating. These tests are usually performed by a neurologist or otorhinolaryngologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=see_link&amp;anchor=H23#H23\">",
"     \"Approach to the patient with vertigo\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete blood count, electrolytes, glucose, electrocardiogram, serum ethanol level urine pregnancy testing (postmenarchal females), and screening for drugs of abuse are often useful to identify causes of pseudovertigo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26102560\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the timely diagnosis of a child who presents with dizziness is to differentiate true vertigo from pseudovertigo. Patients with pseudovertigo may describe a wide variety of symptoms, but will lack a sense of rotation. The history, physical examination, and limited ancillary testing will often point to a cause of pseudovertigo (",
"    <a class=\"graphic graphic_algorithm graphicRef77547 \" href=\"UTD.htm?18/21/18782\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with true vertigo may describe a sensation of spinning and often display nystagmus on physical examination. The sudden onset of symptoms may represent an acute cause of vertigo or the initial presentation of a recurrent cause of vertigo. Patients with true vertigo and a history of trauma should undergo a computed tomography (CT) of the head with temporal bone windows. Those with mental status changes or an abnormal neurologic examination also warrant neuroimaging (MRI or CT). Patients with fever and other signs of meningitis or encephalitis should undergo lumbar puncture, as long as increased intracranial pressure is excluded by physical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuroimaging. Any history of hearing loss or otologic abnormalities should be noted. Other helpful historical details include any recent upper respiratory infections and a family history of migraines. Patients with true vertigo and no findings on physical examination warrant referral to a neurologist or otorhinolaryngologist for advanced vestibular testing if symptoms are prolonged or severe (",
"    <a class=\"graphic graphic_algorithm graphicRef56578 \" href=\"UTD.htm?42/63/44031\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364628\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dizziness describes a disturbed sense of relationship to space. True vertigo refers to the perception that the patient is rotating relative to the environment (subjective vertigo) or that the environment is rotating relative to the patient (objective vertigo). It results from a disturbance somewhere in the vestibular system, which has both peripheral and central nervous system components. Pseudovertigo describes complaints of dizziness without any rotary component. (See",
"      <a class=\"local\" href=\"#H3781563\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Life-threatening, common, and other causes of dizziness are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef51313 \" href=\"UTD.htm?4/53/4957\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26102367\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in the timely diagnosis of a child who presents with dizziness is to differentiate true vertigo from pseudovertigo. Patients with pseudovertigo may describe a wide variety of symptoms, but will lack a sense of rotation. The history, physical examination, and limited ancillary testing will often point to a cause of pseudovertigo (",
"      <a class=\"graphic graphic_algorithm graphicRef77547 \" href=\"UTD.htm?18/21/18782\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26102531\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with true vertigo may describe a sensation of spinning and often display nystagmus on physical examination. The sudden onset of symptoms may represent an acute cause of vertigo or the initial presentation of a recurrent cause of vertigo. The approach to these patients is provided in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef56578 \" href=\"UTD.htm?42/63/44031\">",
"       algorithm 3",
"      </a>",
"      ). Most children will have otitis media, benign paroxysmal vertigo of childhood, or a migraine syndrome as the etiology of their vertigo. However, patients with head trauma, altered mental status, focal neurologic findings, or evidence of central nervous system infection or inflammation warrant neuroimaging and additional evaluation. (See",
"      <a class=\"local\" href=\"#H26102531\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26102560\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dizziness. In: Dorland's Medical Dictionary, 29th, WB Saunders, Philadelphia 2000. p.538.",
"    </li>",
"    <li>",
"     Teach SJ. Dizziness. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig SL, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/3\">",
"      Bower CM, Cotton RT. The spectrum of vertigo in children. Arch Otolaryngol Head Neck Surg 1995; 121:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/4\">",
"      Choung YH, Park K, Moon SK, et al. Various causes and clinical characteristics in vertigo in children with normal eardrums. Int J Pediatr Otorhinolaryngol 2003; 67:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/5\">",
"      Ravid S, Bienkowski R, Eviatar L. A simplified diagnostic approach to dizziness in children. Pediatr Neurol 2003; 29:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/6\">",
"      Riina N, Ilmari P, Kentala E. Vertigo and imbalance in children: a retrospective study in a Helsinki University otorhinolaryngology clinic. Arch Otolaryngol Head Neck Surg 2005; 131:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/7\">",
"      Casselbrant ML, Mandel EM. Balance disorders in children. Neurol Clin 2005; 23:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/8\">",
"      Saka N, Imai T, Seo T, et al. Analysis of benign paroxysmal positional nystagmus in children. Int J Pediatr Otorhinolaryngol 2013; 77:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29064/abstract/9\">",
"      Tusa RJ, Saada AA Jr, Niparko JK. Dizziness in childhood. J Child Neurol 1994; 9:261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13888 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29064=[""].join("\n");
var outline_f28_24_29064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H364628\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26102360\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3781563\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26102367\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102374\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102382\">",
"      - Head trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102389\">",
"      - Central nervous system infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102396\">",
"      - Intracranial tumor or abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102403\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102410\">",
"      - Drug overdose and other poisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102417\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102425\">",
"      - Otitis media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102432\">",
"      - Migraine syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102439\">",
"      - Benign paroxysmal vertigo of childhood (BPVC)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H363944\">",
"      - Adverse effects of medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102453\">",
"      - Motion sickness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102460\">",
"      - Paroxysmal torticollis of infancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3781615\">",
"      - Pseudovertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102467\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102475\">",
"      - Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102482\">",
"      - Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102489\">",
"      - Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102496\">",
"      - Perilymphatic fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102503\">",
"      - Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102510\">",
"      - Ramsay Hunt syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102517\">",
"      - Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26102524\">",
"      - Congenital defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26102531\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102539\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102546\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364247\">",
"      - Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364255\">",
"      - Ear examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364388\">",
"      - Nystagmus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364512\">",
"      - Other vestibular signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364263\">",
"      - Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26102553\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26102560\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364628\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13888|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/27/14770\" title=\"algorithm 1\">",
"      Pediatric algorithm for septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/21/18782\" title=\"algorithm 2\">",
"      Approach to the child with pseudovertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44031\" title=\"algorithm 3\">",
"      Approach to the child with true vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13888|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/32/33285\" title=\"figure 1\">",
"      Normal ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/63/5110\" title=\"figure 2\">",
"      Anatomy VIII cranial nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/32/35330\" title=\"figure 3\">",
"      Dix Hallpike maneuver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13888|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/35/42550\" title=\"picture 1\">",
"      Rtxn pocket cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/8/6272\" title=\"picture 2\">",
"      Cholesteatoma pars flaccida",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/53/4957\" title=\"table 1\">",
"      Causes of dizziness in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/28/37323\" title=\"table 2\">",
"      Clinical characteristics basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/33/30235\" title=\"table 4\">",
"      Clinical features of central versus peripheral vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=related_link\">",
"      Acute mastoiditis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=related_link\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18824?source=related_link\">",
"      Motion sickness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=related_link\">",
"      Pendular nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35640?source=related_link\">",
"      Viral meningitis: Management, prognosis, and prevention in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29065="Zoonoses from dogs";
var content_f28_24_29065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Zoonoses from dogs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Camille N Kotton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29065/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/24/29065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pets serve valuable social roles in society [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Pets may lower blood pressure, reduce cholesterol and triglyceride levels, and improve feelings of loneliness, while increasing opportunities for exercise, outdoor activities, and socialization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small, randomized, controlled study of 28 patients with chronic age-related disabilities living in a nursing home, patients were randomly assigned to animal interaction (\"pet therapy\") compared with usual activities (control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/3\">",
"     3",
"    </a>",
"    ]. The \"pet therapy\" group patients had improved symptoms of depression and a significant decrease in blood pressure values as compared to the control patients.",
"   </p>",
"   <p>",
"    Despite these benefits, pets present zoonotic risks, especially for immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The epidemiology of dog-related zoonoses will be reviewed here. The epidemiology of pet-related zoonoses other than dogs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=see_link\">",
"     \"Zoonoses from pets other than dogs and cats\"",
"    </a>",
"    .) The clinical management of specific zoonotic diseases is discussed under the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A zoonosis is an animal disease that is transmissible to humans. Humans are usually an accidental host that acquire disease through close contact with an infected animal, who may or may not be symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Pet Association estimates that there are approximately 45 million dog owners in the United States, who own a total of about 63 million dogs (",
"    <a class=\"external\" href=\"file://www.apapets.org/\">",
"     file://www.apapets.org",
"    </a>",
"    ). The most common route of infection related to dogs is through bites, especially in children. Dogs bite more than 4.7 million people a year; in 2001, an estimated 368,245 persons were treated in United States hospital emergency departments for nonfatal dog bite-related injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"     \"Soft tissue infections due to dog and cat bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care providers should ask about pets when taking a medical history and formulating a differential diagnosis. Many of the risks posed by pet ownership can be reduced by good hygiene after handling pets, careful pet selection, and proper pet care. New pets can pose more of a health risk because health history and vaccination records may not be known. Adult pets are generally safer than younger animals, since they are less likely to be involved in playful activities that include scratching and biting. Children are at highest risk for infection because they are more likely to have close contact with pets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dogs are responsible for transmission of an extensive array of bacterial and parasitic zoonotic pathogens (",
"    <a class=\"graphic graphic_table graphicRef80280 graphicRef54607 graphicRef67427 \" href=\"UTD.htm?6/6/6254\">",
"     table 1A-C",
"    </a>",
"    ). Many different routes of transmission can cause infections related to pets, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious saliva that contaminate bite wounds, skin abrasions, or mucous membranes",
"     </li>",
"     <li>",
"      Hand-to-mouth transfer of microorganisms, cysts, or oocysts (eggs) from feces of an infected animal",
"     </li>",
"     <li>",
"      Insect bites when these vectors are carried into the home by pets or when bites transmit disease from a pet, acting as a disease reservoir, to humans",
"     </li>",
"     <li>",
"      Aerosol from body fluids (eg, respiratory secretions, placenta)",
"     </li>",
"     <li>",
"      Contamination of water or the environment with pathogen containing animal urine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infectious saliva",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saliva can transmit and contaminate bite wounds, skin abrasions, or mucous membranes. Dog bites are the most common type of animal bite with most bites occurring in children. Bacterial contamination occurs with all animal bites, however, only 5 percent of dog bites develop local infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing countries, dogs account for 90 percent or more of rabies cases transmitted to humans. In contrast, in the United States, wild animals are the major animal reservoirs. While the likelihood of domestic animal (eg, dog and cat) rabies is small in the United States, it varies by region. In the continental United States, rabies among dogs is most often reported along the United States-Mexico border. However, sporadic cases do occur outside of this area, particularly in areas with enzootic wildlife rabies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link\">",
"     \"Rabies immune globulin and vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rabies is a fatal disease in dogs, which can have several phases including the prodromal, furious, and paralytic stages. Dogs are most often infected by the bite of another infected animal. Rabies is transmitted to humans by contaminated saliva through a bite, scratch, or lick of a rabid animal.",
"   </p>",
"   <p>",
"    Human rabies is rare in the United States, with only 47 cases reported between 1990 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/9\">",
"     9",
"    </a>",
"    ]. However, rabies should be considered in the differential diagnosis of patients presenting with acute progressive encephalitis, regardless of a history of an animal bite. Because of the nonspecific early symptoms, other more common infectious and noninfectious disorders (eg, encephalitis caused by arboviruses or enterovirus and Guillain-Barr&eacute; syndrome or vasculitis) should be ruled out (",
"    <a class=\"graphic graphic_algorithm graphicRef79957 \" href=\"UTD.htm?30/11/30896\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pasteurella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pasteurella spp can serve as either commensals or pathogens in animals and can be found in the oral cavity of dogs (P. canis and P. dogmatis). Pasteurella spp have been the most frequent isolates from both dog and cat bites (50 and 75 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/10\">",
"     10",
"    </a>",
"    ]. The infection rate from penetrating dog bites ranges from 2 to 10 percent.",
"   </p>",
"   <p>",
"    Pasteurella can cause soft-tissue infections following animal bites or scratches; bites and scratches can also result in septic arthritis and osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link\">",
"     \"Pasteurella infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Capnocytophaga",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capnocytophaga was first isolated in 1976 from the blood and CSF of a patient who had received a dog bite [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/11\">",
"     11",
"    </a>",
"    ]. Capnocytophaga canimorsus (formerly CDC group DF-2) is a fastidious, gram-negative rod that forms part of the normal oral flora of dogs and cats.",
"   </p>",
"   <p>",
"    Both C. canimorsus and C. cynodegmi cause human infection, often following a dog or cat bite or scratch [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/12\">",
"     12",
"    </a>",
"    ]. C. canimorsus can cause fulminant sepsis and meningitis, particularly in asplenic patients or alcoholics. The mortality rate for C. canimorsus septicemia is 30 to 36 percent but mortality due to meningitis is much lower (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    C. cynodegmi animal bite wound infections are a less severe infection that is usually restricted to skin and soft tissues, although a case report described the death of a splenectomized woman who received a dog bite and developed C. cynodegmi sepsis and meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Brucella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucella canis infection in dogs appears to have a worldwide distribution, but human infections with B. canis are either uncommon or uncommonly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/17\">",
"     17",
"    </a>",
"    ]. Instead, the Brucella spp that are frequently associated with human brucellosis are B. melitensis, B. suis, and B. abortus. Humans may become infected when they are exposed to body fluids from a B. canis infected dog. Most cases of human transmission from dogs are in farm settings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human brucellosis is a well-documented cause of fever of unknown origin with varied and nonspecific symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fecal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common zoonotic pathogens causing canine gastroenteritis include Salmonella, Campylobacter, Cryptosporidium and Giardia; dogs with diarrhea should have a stool specimen examined for these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, numerous parasitic diseases can be transmitted from dogs to humans through feces, including toxocariasis, cutaneous larva migrans (Ancylostoma caninum and A. braziliense), echinococcosis, and dipylidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Salmonella",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1999 and 2000, four outbreaks of gastrointestinal illness due to multi-drug resistant Salmonella enterica serotype Typhimurium were reported in employees, clients, and animals from three veterinary clinics and one animal shelter; more than 45 persons and pets became ill [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salmonella can also be transmitted via contaminated pet food [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/23\">",
"     23",
"    </a>",
"    ] and through animal-derived pet treats, including pig ear treats, beef steak patty dog treats, and pet treats of seafood origin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/24\">",
"     24",
"    </a>",
"    ]. To prevent such infection, individuals should wash their hands with soap and water after handling dry pet foods, especially before handling food for humans. In contrast, the manufacturing process for canned pet food should eliminate bacterial contamination.",
"   </p>",
"   <p>",
"    Salmonella spp infections transmitted to humans usually result in a mild, self-limiting gastroenteritis. However, severe invasive illness, such as septicemia or meningitis, can occur especially in infants and immunocompromised persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Campylobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surveillance study of possible animal reservoirs of Campylobacter spp in Barbados identified that 61 of 130 pet dogs (47 percent) had Campylobacter spp isolated from fecal specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/25\">",
"     25",
"    </a>",
"    ]. Direct zoonotic transmission of Campylobacter from contact with dogs and puppies (one of which resulted in neonatal sepsis) has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Campylobacter enteritis presents after an incubation period of one to seven days as a syndrome most commonly characterized by prominent abdominal pain and profuse diarrhea that is often bloody. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Giardia lamblia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giardia lamblia (also known as G. duodenalis or G. intestinalis) is a flagellated protozoan parasite and one of the most common gastrointestinal parasites in the United States. The greatest risk of zoonotic transmission appears to be from pets, especially dogs and cats. A surveillance study of G. intestinalis isolates obtained from children with diarrhea and their dogs, found that genotype A was associated with zoonotic transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The spectrum of clinical disease includes asymptomatic infection, self-limited acute giardiasis, and chronic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Toxocara canis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxocara canis (dog roundworm) causes visceral larva migrans and ocular larva migrans in humans. These roundworms live in the small intestine of the dog in the adult stage, where eggs are passed in the feces. Up to 15 percent of healthy older dogs actively excrete T. canis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/31\">",
"     31",
"    </a>",
"    ]. In endemic areas, empiric treatment of dogs lowered the rate of Toxocara infection in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human infections are caused by ingestion of eggs from contaminated hands, soil, or fomites and are usually asymptomatic to mild and accompanied by a persistent eosinophilia. The larvae penetrate the intestinal wall but are unable to complete their life cycle and produce eosinophilic granulomas in host tissues. Infection produces a syndrome in humans termed visceral larva migrans or toxocariasis. This disorder may be subclinical; it also may present primarily as an ocular form. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=see_link\">",
"     \"Toxocariasis: visceral and ocular larva migrans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic toxocariasis most often affects children aged one to four. Clinical manifestations include eosinophilia, rash, fever, cough, weight loss, hepatosplenomegaly, pulmonary infiltrates, seizures, and behavior disorders. Ocular larva migrans often presents in older children with a unilateral reduction in vision or strabismus and often with retinal involvement but without the systemic symptoms or eosinophilia seen in visceral disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ancylostoma caninum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hookworm Ancylostoma caninum and A. braziliense are the etiologic agents of cutaneous larva migrans. The eggs are shed in the feces of infected dogs or cats. In the United States, the dog hookworm, A. caninum, is a commonly occurring parasite.",
"   </p>",
"   <p>",
"    Humans (and pets) are infected when bare skin comes in contact with soil contaminated with the larvae. The second-stage larvae are able to penetrate the intact skin of humans and the footpads of dogs and cats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=see_link\">",
"     \"Cutaneous larva migrans (creeping eruption)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pruritic erythematous papule develops initially at the site of each larval entry. Two to three days later, and at times weeks later, severely pruritic, elevated, serpiginous, reddish-brown lesions appear as the larvae migrate at a rate of several millimeters per day (",
"    <a class=\"graphic graphic_picture graphicRef60144 \" href=\"UTD.htm?39/63/40944\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Echinococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dogs and other carnivorous mammals are the definitive hosts for the tapeworm, Echinococcus granulosus. The adult tapeworm inhabits the small intestine of the dog and can produce eggs that are expelled in the feces contaminating the environment. They are infective to humans. Human disease is most common in ranching areas of the Mediterranean, South America, and Australia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20407?source=see_link\">",
"     \"Epidemiology and control of echinococcosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In humans, ingested eggs enter the portal circulation and spread to the liver and other tissues, where they are either destroyed or form hydatid cysts. The cysts slowly enlarge over years, due to the multiplying larvae inside. The most common sites of infection in humans are the liver, lung, bone, kidney, and brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dipylidium caninum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dog tapeworm, Dipylidium caninum, commonly infects domestic cats and dogs and may also accidentally infect humans. Fleas usually serve as the intermediate hosts and contain cysticercoids. If a human (usually a child) ingests cysticercoids (larva), an adult tapeworm can develop in the intestine.",
"   </p>",
"   <p>",
"    This infection is usually asymptomatic. However, abdominal pain, diarrhea, pruritus ani, and urticaria can develop. In addition, parents may notice the passage of proglottids (eg, body segments of the adult tapeworm, which have a complete set of reproductive organs) that resemble cucumber seeds in their children's stool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=see_link\">",
"     \"Intestinal tapeworms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Insect bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dogs can transport ticks or fleas, which may subsequently bite a human host and transmit infectious diseases. In addition, an infected dog may act as a reservoir of disease borne by other arthropod vectors, such as mosquitoes and sand flies, which in turn, after feeding on the dog, can transmit disease to humans by their bite.",
"   </p>",
"   <p>",
"    Ticks can carry many diseases, including Borrelia burgdorferi (Lyme disease), Ehrlichia (ehrlichiosis), Babesia microti (babesiosis), Francisella tularensis (tularemia), and Rickettsia rickettsii (Rocky Mountain Spotted Fever). Fleas carried by dogs can bite a human host and transmit plague. Mosquitoes can transmit dirofilariasis and sand flies can transmit leishmaniasis from the dog reservoir to humans by their bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is caused by B. burgdorferi, which is spread by the bite of infected Ixodes ticks (",
"    <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"     picture 2",
"    </a>",
"    ). Approximately 95 percent of cases of Lyme disease in the United State are reported from twelve states: Massachusetts, Connecticut, Maine, New Hampshire, Rhode Island, New York, New Jersey, Pennsylvania, Delaware, Maryland, Michigan, and Wisconsin.",
"   </p>",
"   <p>",
"    In highly endemic areas, dog owners should inspect their pets regularly for ticks, as tick collars have a variable efficacy. Owners should inspect their cats for ticks for two reasons. First, dogs can develop Lyme disease, which presents as sudden onset lameness with a swollen, warm, and tender joint. Second, dogs may carry ticks indoors, and if these ticks carry B. burgdorferi and attach to a human, they may then transmit Lyme disease to the pet's human family. Dogs have served as sentinel animals to assess the prevalence of B. burgdorferi infection in ticks in a region [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human Lyme disease is a multisystem inflammatory disease. One of the first clinical manifestations is the classic erythema migrans (EM) skin lesion (",
"    <a class=\"graphic graphic_picture graphicRef81270 \" href=\"UTD.htm?10/10/10400\">",
"     picture 3",
"    </a>",
"    ) that occurs in up to 90 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Rocky Mountain spotted fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal vector of Rocky Mountain spotted fever (RMSF) in the eastern and south central United States is Dermacentor variabilis (the American dog tick) (",
"    <a class=\"graphic graphic_picture graphicRef71719 \" href=\"UTD.htm?19/57/20383\">",
"     picture 4",
"    </a>",
"    ) and Dermacentor andersonii (the Rocky Mountain wood tick) (",
"    <a class=\"graphic graphic_picture graphicRef68829 \" href=\"UTD.htm?21/18/21806\">",
"     picture 5",
"    </a>",
"    ) in the mountain states west of the Mississippi River. Dogs develop rickettsial infection when bitten by infected ticks and then act as a source of infection for other feeding ticks. These ticks may then transmit infection to other dogs or their owners. Dogs may serve as environmental sentinels for establishing the geographic prevalence of foci of spotted fever [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous case reports have described concurrent RMSF in dogs and their owners [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. In an outbreak of RMSF with a newly identified vector (the common brown dog tick, Rhipicephalus sanguineus) (",
"    <a class=\"graphic graphic_picture graphicRef72221 \" href=\"UTD.htm?2/23/2431\">",
"     picture 6",
"    </a>",
"    ) in Arizona, all patients with confirmed disease had contact with tick-infected dogs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/41\">",
"     41",
"    </a>",
"    ]. In the United States, RMSF is most prevalent in the southeastern and south central states, with North Carolina and Arkansas accounting for the largest numbers of cases.",
"   </p>",
"   <p>",
"    The clinical spectrum of human infection with R. rickettsii ranges from mild to fulminant. In the early phases of illness, most patients have nonspecific signs and symptoms such as fever, headache that is often severe, malaise, myalgias, arthralgias, and nausea with or without vomiting. Most patients develop a rash between the third and fifth days of illness (",
"    <a class=\"graphic graphic_picture graphicRef58061 \" href=\"UTD.htm?39/20/40270\">",
"     picture 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ehrlichiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important human ehrlichial diseases are human monocytic ehrlichiosis (HME), which is caused by E. chaffeensis, and human granulocytic anaplasmosis (HGA), which is caused by Anaplasma phagocytophilum. The principle vector of E. chaffeensis is thought to be the Lone Star tick (",
"    <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"     picture 8",
"    </a>",
"    ) (Amblyomma americanum, whose primary host is deer). A. phagocytophilum, in contrast, may be transmitted by Ixodes scapularis (",
"    <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"     picture 2",
"    </a>",
"    ), the tick that is also the vector of Lyme disease and babesiosis (see below). Most cases of HME have occurred in the southeastern, south-central, and mid-Atlantic regions of the United States. States with the highest incidence of HGA during 2001 to 2002 were Rhode Island, Minnesota, Connecticut, New York, and Maryland. HGA is also reported in Western Europe.",
"   </p>",
"   <p>",
"    E. ewingii, the agent of canine granulocytic ehrlichiosis can cause disease in humans. Cases of E. ewingii human disease with clinical features of illness similar to HME were reported from Missouri [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/42\">",
"     42",
"    </a>",
"    ]. Polymerase chain reaction (PCR) distinguished the E. ewingii organism from E. chaffeensis; morules were observed in granulocytes in two of the patients; and one patient's dogs displayed a similar serologic reaction as the patient, suggesting zoonotic transmission.",
"   </p>",
"   <p>",
"    The clinical manifestations of HME and HGA are variable. Most patients are febrile with nonspecific symptoms including malaise, myalgia, headache, and chills. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Babesiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesiosis is a tick-borne illness caused by malaria-like parasites that infect red blood cells and result in hemolysis. Human disease is most commonly due to Babesia microti (United States) or Babesia divergens (Europe). The vector for babesiosis is the Ixodid tick, the same vector as Lyme disease and anaplasmosis. Babesiosis occurs predominantly on the Northeast coast of the United States.",
"   </p>",
"   <p>",
"    The clinical manifestations of disease can range from asymptomatic infection to severe hemolytic anemia associated with jaundice, hemoglobinuria, renal failure, and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=see_link\">",
"     \"Epidemiology and pathogenesis of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Tularemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is a zoonosis caused by the gram-negative bacterium, Francisella tularensis. Humans are accidental hosts following contact with infected animals or vectors. In the United States, tularemia has been reported from 49 states, but the majority of cases occur in the south central states, mainly Arkansas, Missouri, and Oklahoma. Vector-borne disease, by ticks in the Rocky Mountain region and eastward and biting flies in California, Nevada, and Utah, are the most common way the disease is transmitted in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients infected with Francisella spp present with the abrupt onset of fever, chills, headache, and malaise, after an incubation period of 2 to 10 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Yersinia pestis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yersinia pestis is the etiologic agent of plague. Dogs are susceptible to infection and may be a significant sentinel animal. Dogs become infected after being bitten by rodents' fleas and have a brief and self-limited illness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/5\">",
"     5",
"    </a>",
"    ]. They can carry the infected fleas, which can spread disease to humans through a fleabite. Foci of plague are present on most continents other than Australia. In the United States, plague is endemic in all of the western states and has extended north and east over the years. Ninety percent of human cases in the United States have occurred in four states: Arizona, California, Colorado, and New Mexico. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three generally recognized clinical syndromes are associated with plague: bubonic, septicemic, and pneumonic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Dirofilaria immitis (Dog heartworm)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dirofilaria immitis, the dog heartworm, is a vascular parasite, with the adult worm residing in the pulmonary artery and right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/43\">",
"     43",
"    </a>",
"    ]. Most dogs are asymptomatic, but some animals may have exercise intolerance, hemoptysis, or signs of right ventricular outflow obstruction. Dirofilariasis is particularly common in the Mediterranean region but has been reported from many different countries, including the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=see_link\">",
"     \"Miscellaneous nematodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The organism is transmitted to humans by Aedes, Anopheles, Culex, or Myzorhynchus mosquitoes, which ingest blood-containing microfilaria from affected dogs. Two clinical syndromes of dirofilariasis occur in humans, pulmonary and cutaneous infection. Cutaneous infection occurs when the larva die after inoculation into the subcutaneous tissue and cause an urticarial eruption. If a larva survives and reaches the heart, it dies and forms an embolus, which travels to the lungs resulting in focal pneumonitis followed by granuloma formation. The pulmonary emboli are identified as a \"coin lesion\" on radiograph and the diagnosis of dirofilariasis is made when the lesion, appearing to be a neoplasm, is removed surgically. There are no medications used to treat humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=see_link\">",
"     \"Miscellaneous nematodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Leishmania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmaniasis is caused by a heterogeneous group of protozoan parasites belonging to the genus Leishmania. Humans and mammals, including the dog, are reservoirs for the disease. Female sand flies transmit the disease from an infected mammal to humans. In a serologic surveillance study in Iran, dog ownership and dog density in a village was a significant risk factor for seropositivity in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/44\">",
"     44",
"    </a>",
"    ]. Attempts at dog culling to reduce the incidence of leishmaniasis have not been successful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most human infections with Leishmania are asymptomatic. However, when they cause symptoms, Leishmania spp can cause cutaneous, mucocutaneous, or visceral disease. (See",
"    <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=see_link\">",
"     \"Clinical manifestations and diagnosis of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Aerosol",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Bordetella bronchiseptica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bordetella bronchiseptica causes kennel cough in dogs, snuffles in rabbits, and atrophic rhinitis in piglets. Healthy dogs may harbor small numbers of this bacterium in their oropharynx.",
"   </p>",
"   <p>",
"    Although rare, human infection with B. bronchiseptica has been documented in both healthy and immunocompromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Of nine HIV patients from whom B. bronchiseptica was isolated, respiratory illnesses ranged from mild upper respiratory tract infections to pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/50\">",
"     50",
"    </a>",
"    ]. Two of these persons had household contact with dogs prior to their illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Coxiella burnetii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxiella burnetii, the etiologic agent of Q fever, is a worldwide zoonosis. The most commonly identified sources of human infection are farm animals, but dogs may also rarely serve as a source [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Infected mammals shed C. burnetii in urine, feces, milk, and birth products. Infected dogs may be asymptomatic, but infection may cause abortion or rapid death of newborn pups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/51\">",
"     51",
"    </a>",
"    ]. A serologic survey on 429 dogs from France found 9.8 percent were positive for Coxiella burnetii; dogs that had contact with sheep were more likely to be seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, exposure results from inhalation of contaminated aerosols from parturient fluids of infected mammals, which can be present in the environment, on the coats of newborn animals, or from the placenta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=see_link\">",
"     \"Microbiology and epidemiology of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical signs of Q fever are often extremely mild or absent. Patients may be asymptomatic or can present acutely with one of three clinical presentations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A self-limited flu-like illness",
"     </li>",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Hepatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case report describes the development of Coxiella burnetii pneumonia in all three members of one family, 8 to 12 days after exposure to an infected parturient dog [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic infection most commonly involves the heart as endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Contaminated urine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Leptospirosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospira interrogans, the etiologic agent of human leptospirosis, infects a variety of both wild and domestic mammals, including dogs. Animals can be asymptomatic or develop clinical infection, which can be fatal. Mortality in dogs is estimated at 10 percent. Transmission to humans occurs by contact with water or soil contaminated with the urine of infected animals (predominantly rats). A case-control study of an outbreak in rural Nicaragua in 1995 found that owning an infected dog was a significant risk factor for disease (matched odds ratio 23.4; 95% CI, 3.6 to infinity) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/54\">",
"     54",
"    </a>",
"    ]. Outbreaks of dog-associated leptospirosis have also been reported in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leptospirosis may manifest as a subclinical illness followed by seroconversion, a self-limited systemic infection, or a severe, potentially fatal illness accompanied by multiorgan failure.",
"   </p>",
"   <p>",
"    Leptospirosis usually presents with the abrupt onset of fever, rigors, myalgias, and headache, after an incubation period of 2 to 26 days (average 10 days). Many patients have an associated nonproductive cough, nausea, vomiting, and diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Direct contact",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Methicillin-resistant Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin-resistant Staphylococcus aureus (MRSA) appears to be an emerging veterinary and zoonotic pathogen. Transmission between infected or colonized domestic pets and humans in veterinary clinics and in households has been documented, both animal-to-human and human-to-animal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/56\">",
"     56",
"    </a>",
"    ]. The transmission may be clinically relevant as illustrated by a case of recurrent MRSA infection in a patient with diabetes and his wife [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/36\">",
"     36",
"    </a>",
"    ]. Further recurrence of MRSA infection was prevented only after successful eradication of asymptomatic nasal carriage of MRSA in the family's pet dog. In a study where S. aureus was isolated concurrently from humans and their pet dogs or cats, 50 percent of cases showed strains that were indistinguishable from human and pets, suggesting significant rates of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other resistant organisms, such as E. coli, can be passed from pets to owners and will likely increase as more pets are exposed to cephalosporins, fluoroquinolones, and other antibiotics that exert positive selective pressure for resistant bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     General precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although dogs have been implicated in transmission of zoonoses to their owners, risk of transmission from contact with dogs is low and may be further reduced by simple precautions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dogs should be seen by a veterinarian on a regular basis, treated promptly for diarrhea, vaccinated for rabies, and treated to prevent heartworm disease (Dirofilaria immitis).",
"     </li>",
"     <li>",
"      Effective flea control requires treatment of affected dogs, their environment, and other animals they contact.",
"     </li>",
"     <li>",
"      Dogs should be fed high quality commercial food and should not eat raw meat or eggs. A survey of dogs fed raw meat found higher rates of Campylobacter and Salmonella in their stools [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/59\">",
"       59",
"      </a>",
"      ]. They should not be allowed to eat garbage, feces, or hunt [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/6\">",
"       6",
"      </a>",
"      ]. They should not be allowed to drink non-potable water (eg, surface water or toilet water).",
"     </li>",
"     <li>",
"      Dogs should be inspected for ticks regularly",
"     </li>",
"     <li>",
"      Owners should wash their hands following contact with or cleaning up dog feces.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups at high risk for serious infection from pets include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons with waning immunity (eg, older adults)",
"     </li>",
"     <li>",
"      Children less than five years old",
"     </li>",
"     <li>",
"      Pregnant women",
"     </li>",
"     <li>",
"      Immunocompromised patients with AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/60\">",
"       60",
"      </a>",
"      ] and those without a functioning spleen or taking immunosuppressive therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous reports exist of the transmission of zoonoses to humans during and after solid organ and hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/61\">",
"     61",
"    </a>",
"    ]. Most zoonoses present as a primary infection in the posttransplant period; immunocompromised patients are more likely to experience significant morbidity and mortality from these infections.",
"   </p>",
"   <p>",
"    To avoid infections, people at higher risk should take particular precautions with any animal contact. In addition to thorough and frequent hand washing, these precautions might include avoiding contact with animals and their environment (eg, pens, bedding, and manure). For children, risk for exposure might be reduced if they are closely supervised by adults, carried by adults in animal areas, or have animal contact only over a barrier. These measures discourage animals from jumping on or nuzzling children and minimize contact with feces and soiled bedding.",
"   </p>",
"   <p>",
"    The United States Public Health Service and the Infectious Diseases Society of America have issued formal recommendation for HIV positive people who desire pet contact [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/21\">",
"     21",
"    </a>",
"    ]. The guidelines specify:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When obtaining a new pet, HIV-infected persons should avoid animals aged &lt;6 months (or &lt;1 year for cats) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-infected persons should be cautious when obtaining a pet from pet-breeding facilities, pet stores, and animal shelters, because of highly variable hygienic and sanitary conditions. Stray animals should be avoided.",
"     </li>",
"     <li>",
"      HIV-infected persons should avoid contact with any animal that has diarrhea. HIV-infected pet owners should seek veterinary care for animals with diarrheal illness, and a fecal sample from such animals should be examined for Cryptosporidium, Salmonella, and Campylobacter.",
"     </li>",
"     <li>",
"      HIV-infected persons should wash their hands after handling pets, including before eating, and should avoid contact with pets' feces.",
"     </li>",
"     <li>",
"      HIV-infected persons should avoid contact with reptiles (eg, snakes, lizards, iguanas, and turtles) as well as chicks and ducklings because of the risk for salmonellosis.",
"     </li>",
"     <li>",
"      Gloves should be used during aquarium cleaning to reduce the risk for infection with Mycobacterium marinum.",
"     </li>",
"     <li>",
"      Contact with exotic pets (eg, nonhuman primates) should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Centers for Disease Control offer a \"Pet-Scription\" at",
"    <a class=\"external\" href=\"file://www.cdc.gov/healthypets/health_prof.htm\">",
"     file://www.cdc.gov/healthypets/health_prof.htm#petscription",
"    </a>",
"    which provides patients with more information about pet and infection risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Public health education",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey of knowledge and perceptions of dog-associated zoonoses uncovered a major lack of knowledge in the general public. While 98 percent of respondents had heard of rabies and knew that acquisition was possible from a dog, only 59 percent of respondents were aware that exposure to rabies without treatment could lead to death, and only 54 percent of respondents knew that worms could be transmitted from dogs to people [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29065/abstract/63\">",
"     63",
"    </a>",
"    ]. As roughly half of households in the USA have a dog, better public knowledge about zoonoses might mitigate transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"       \"Patient information: Animal bites (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A zoonosis is an animal disease that is transmissible to humans. Humans are usually an accidental host that acquire disease through close contact with an infected animal, who may or may not be symptomatic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children are at highest risk for infection because they are more likely to have close contact with pets. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dogs are responsible for transmission of an extensive array of bacterial and parasitic zoonotic pathogens. The route of transmission can be through the feces, urine, saliva (eg, bites or contaminated scratches), or respiratory secretions of the animal, or by the dog or cat acting as a vehicle and source of tick or flea exposure or reservoir for vector borne disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although dogs have been implicated in transmission of zoonoses to their owners, risk of transmission from contact with dogs is low and may be further reduced by simple precautions. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/1\">",
"      Anderson WP, Reid CM, Jennings GL. Pet ownership and risk factors for cardiovascular disease. Med J Aust 1992; 157:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/2\">",
"      Parslow RA, Jorm AF. Pet ownership and risk factors for cardiovascular disease: another look. Med J Aust 2003; 179:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/3\">",
"      Stasi MF, Amati D, Costa C, et al. Pet-therapy: a trial for institutionalized frail elderly patients. Arch Gerontol Geriatr Suppl 2004; :407.",
"     </a>",
"    </li>",
"    <li>",
"     Bisseru B. Disease of Man Acquired from His Pets, J. B. Lippincott Company, Philadelphia 1967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/5\">",
"      Elliot DL, Tolle SW, Goldberg L, Miller JB. Pet-associated illness. N Engl J Med 1985; 313:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/6\">",
"      Trevejo RT, Barr MC, Robinson RA. Important emerging bacterial zoonotic infections affecting the immunocompromised. Vet Res 2005; 36:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal dog bite-related injuries treated in hospital emergency departments--United States, 2001. MMWR Morb Mortal Wkly Rep 2003; 52:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/8\">",
"      Riordan A, Tarlow M. Pets and diseases. Br J Hosp Med 1996; 56:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Human rabies--Florida, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/10\">",
"      Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/11\">",
"      Bobo RA, Newton EJ. A previously undescribed gram-negative bacillus causing septicemia and meningitis. Am J Clin Pathol 1976; 65:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/12\">",
"      Brenner DJ, Hollis DG, Fanning GR, Weaver RE. Capnocytophaga canimorsus sp. nov. (formerly CDC group DF-2), a cause of septicemia following dog bite, and C. cynodegmi sp. nov., a cause of localized wound infection following dog bite. J Clin Microbiol 1989; 27:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/13\">",
"      Pers C, Gahrn-Hansen B, Frederiksen W. Capnocytophaga canimorsus septicemia in Denmark, 1982-1995: review of 39 cases. Clin Infect Dis 1996; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/14\">",
"      Lion C, Escande F, Burdin JC. Capnocytophaga canimorsus infections in human: review of the literature and cases report. Eur J Epidemiol 1996; 12:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/15\">",
"      Le Moal G, Landron C, Grollier G, et al. Meningitis due to Capnocytophaga canimorsus after receipt of a dog bite: case report and review of the literature. Clin Infect Dis 2003; 36:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/16\">",
"      Khawari AA, Myers JW, Ferguson DA Jr, Moorman JP. Sepsis and meningitis due to Capnocytophaga cynodegmi after splenectomy. Clin Infect Dis 2005; 40:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/17\">",
"      Lucero NE, Jacob NO, Ayala SM, et al. Unusual clinical presentation of brucellosis caused by Brucella canis. J Med Microbiol 2005; 54:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/18\">",
"      Rumley RL, Chapman SW. Brucella canis: an infectious cause of prolonged fever of undetermined origin. South Med J 1986; 79:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/19\">",
"      Forbes LB. Brucella abortus infection in 14 farm dogs. J Am Vet Med Assoc 1990; 196:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/20\">",
"      Mishal J, Ben-Israel N, Levin Y, et al. Brucellosis outbreak: analysis of risk factors and serologic screening. Int J Mol Med 1999; 4:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/21\">",
"      Kaplan JE, Masur H, Holmes KK, et al. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/22\">",
"      Wright JG, Tengelsen LA, Smith KE, et al. Multidrug-resistant Salmonella Typhimurium in four animal facilities. Emerg Infect Dis 2005; 11:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Update: recall of dry dog and cat food products associated with human Salmonella Schwarzengrund infections--United States, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/24\">",
"      Finley R, Reid-Smith R, Ribble C, et al. The occurrence and anti-microbial susceptibility of Salmonellae isolated from commercially available pig ear pet treats. Zoonoses Public Health 2008; 55:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/25\">",
"      Workman SN, Mathison GE, Lavoie MC. Pet dogs and chicken meat as reservoirs of Campylobacter spp. in Barbados. J Clin Microbiol 2005; 43:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/26\">",
"      Damborg P, Olsen KE, M&oslash;ller Nielsen E, Guardabassi L. Occurrence of Campylobacter jejuni in pets living with human patients infected with C. jejuni. J Clin Microbiol 2004; 42:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/27\">",
"      Wolfs TF, Duim B, Geelen SP, et al. Neonatal sepsis by Campylobacter jejuni: genetically proven transmission from a household puppy. Clin Infect Dis 2001; 32:E97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/28\">",
"      Thompson RC. The zoonotic significance and molecular epidemiology of Giardia and giardiasis. Vet Parasitol 2004; 126:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/29\">",
"      Eligio-Garc&iacute;a L, Cortes-Campos A, Jim&eacute;nez-Cardoso E. Genotype of Giardia intestinalis isolates from children and dogs and its relationship to host origin. Parasitol Res 2005; 97:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/30\">",
"      Traub RJ, Monis PT, Robertson I, et al. Epidemiological and molecular evidence supports the zoonotic transmission of Giardia among humans and dogs living in the same community. Parasitology 2004; 128:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/31\">",
"      Glickman LT, Schantz PM, Cypess RH. Canine and human toxocariasis: review of transmission, pathogenesis, and clinical disease. J Am Vet Med Assoc 1979; 175:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/32\">",
"      Coelho LM, Silva MV, Dini CY, et al. Human toxocariasis: a seroepidemiological survey in schoolchildren of Sorocaba, Brazil. Mem Inst Oswaldo Cruz 2004; 99:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/33\">",
"      Duncan AW, Correa MT, Levine JF, Breitschwerdt EB. The dog as a sentinel for human infection: prevalence of Borrelia burgdorferi C6 antibodies in dogs from southeastern and mid-Atlantic states. Vector Borne Zoonotic Dis 2004; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/34\">",
"      Johnson JL, Ginsberg HS, Zhioua E, et al. Passive tick surveillance, dog seropositivity, and incidence of human lyme disease. Vector Borne Zoonotic Dis 2004; 4:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/35\">",
"      Lindenmayer JM, Marshall D, Onderdonk AB. Dogs as sentinels for Lyme disease in Massachusetts. Am J Public Health 1991; 81:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/36\">",
"      Breitschwerdt EB, Moncol DJ, Corbett WT, et al. Antibodies to spotted fever-group rickettsiae in dogs in North Carolina. Am J Vet Res 1987; 48:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/37\">",
"      Gordon JC, Gordon SW, Peterson E, Philip RN. Epidemiology of Rocky Mountain spotted fever in Ohio, 1981: serologic evaluation of canines and rickettsial isolation from ticks associated with human case exposure sites. Am J Trop Med Hyg 1984; 33:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/38\">",
"      Magnarelli LA, Anderson JF, Philip RN, Burgdorfer W. Antibodies to spotted fever-group rickettsiae in dogs and prevalence of infected ticks in southern Connecticut. Am J Vet Res 1982; 43:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/39\">",
"      Paddock CD, Brenner O, Vaid C, et al. Short report: concurrent Rocky Mountain spotted fever in a dog and its owner. Am J Trop Med Hyg 2002; 66:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/40\">",
"      Sexton DJ, Burgdorfer W, Thomas L, Norment BR. Rocky Mountain spotted fever in Mississippi: survey for spotted fever antibodies in dogs and for spotted fever group reckettsiae in dog ticks. Am J Epidemiol 1976; 103:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/41\">",
"      Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005; 353:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/42\">",
"      Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/43\">",
"      Theis JH. Public health aspects of dirofilariasis in the United States. Vet Parasitol 2005; 133:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/44\">",
"      Gavgani AS, Mohite H, Edrissian GH, et al. Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. Am J Trop Med Hyg 2002; 67:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/45\">",
"      Moreira ED Jr, Mendes de Souza VM, Sreenivasan M, et al. Assessment of an optimized dog-culling program in the dynamics of canine Leishmania transmission. Vet Parasitol 2004; 122:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/46\">",
"      Lo Re V 3rd, Brennan PJ, Wadlin J, et al. Infected branchial cleft cyst due to Bordetella bronchiseptica in an immunocompetent patient. J Clin Microbiol 2001; 39:4210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/47\">",
"      Stefanelli P, Mastrantonio P, Hausman SZ, et al. Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs. J Clin Microbiol 1997; 35:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/48\">",
"      Woolfrey BF, Moody JA. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev 1991; 4:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/49\">",
"      Goldberg JD, Kamboj M, Ford R, et al. 'Kennel cough' in a patient following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2009; 44:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/50\">",
"      Dworkin MS, Sullivan PS, Buskin SE, et al. Bordetella bronchiseptica infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 28:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/51\">",
"      Buhariwalla F, Cann B, Marrie TJ. A dog-related outbreak of Q fever. Clin Infect Dis 1996; 23:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/52\">",
"      Komiya T, Sadamasu K, Toriniwa H, et al. Epidemiological survey on the route of Coxiella burnetii infection in an animal hospital. J Infect Chemother 2003; 9:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/53\">",
"      Boni M, Davoust B, Tissot-Dupont H, Raoult D. Survey of seroprevalence of Q fever in dogs in the southeast of France, French Guyana, Martinique, Senegal and the Ivory Coast. Vet Microbiol 1998; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/54\">",
"      Trevejo RT, Rigau-P&eacute;rez JG, Ashford DA, et al. Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995. J Infect Dis 1998; 178:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/55\">",
"      Feigin RD, Lobes LA Jr, Anderson D, Pickering L. Human leptospirosis from immunized dogs. Ann Intern Med 1973; 79:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/56\">",
"      Weese JS, Dick H, Willey BM, et al. Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household. Vet Microbiol 2006; 115:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/57\">",
"      Hanselman BA, Kruth SA, Rousseau J, Weese JS. Coagulase positive staphylococcal colonization of humans and their household pets. Can Vet J 2009; 50:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/58\">",
"      Lloyd DH. Reservoirs of antimicrobial resistance in pet animals. Clin Infect Dis 2007; 45 Suppl 2:S148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/59\">",
"      Lenz J, Joffe D, Kauffman M, et al. Perceptions, practices, and consequences associated with foodborne pathogens and the feeding of raw meat to dogs. Can Vet J 2009; 50:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/60\">",
"      Glaser CA, Angulo FJ, Rooney JA. Animal-associated opportunistic infections among persons infected with the human immunodeficiency virus. Clin Infect Dis 1994; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/61\">",
"      Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007; 44:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/62\">",
"      Robinson RA, Pugh RN. Dogs, zoonoses and immunosuppression. J R Soc Promot Health 2002; 122:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29065/abstract/63\">",
"      Bingham GM, Budke CM, Slater MR. Knowledge and perceptions of dog-associated zoonoses: Brazos County, Texas, USA. Prev Vet Med 2010; 93:211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5529 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29065=[""].join("\n");
var outline_f28_24_29065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infectious saliva",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rabies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pasteurella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Capnocytophaga",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Brucella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fecal transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Salmonella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Giardia lamblia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Toxocara canis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ancylostoma caninum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Echinococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dipylidium caninum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ehrlichiosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Babesiosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Tularemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Yersinia pestis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Dirofilaria immitis (Dog heartworm)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Leishmania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Aerosol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Bordetella bronchiseptica",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Coxiella burnetii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Contaminated urine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Direct contact",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      General precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Public health education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5529|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/11/30896\" title=\"algorithm 1\">",
"      Differential dx rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5529|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/63/40944\" title=\"picture 1\">",
"      Cutaneous larva migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/13/14558\" title=\"picture 2\">",
"      Ixodes scapularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/10/10400\" title=\"picture 3\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/57/20383\" title=\"picture 4\">",
"      American dog tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/18/21806\" title=\"picture 5\">",
"      Rocky mountain wood tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/23/2431\" title=\"picture 6\">",
"      Brown dog tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/20/40270\" title=\"picture 7\">",
"      RMSF rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23582\" title=\"picture 8\">",
"      Lone star tick",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/52/28492\" title=\"table 1A\">",
"      Zoonoses from dogs A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/23/22908\" title=\"table 1B\">",
"      Zoonoses from dogs B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/45/19163\" title=\"table 1C\">",
"      Zoonoses from dogs C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis?source=related_link\">",
"      Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29624?source=related_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=related_link\">",
"      Clinical manifestations and diagnosis of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=related_link\">",
"      Cutaneous larva migrans (creeping eruption)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20407?source=related_link\">",
"      Epidemiology and control of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=related_link\">",
"      Epidemiology and pathogenesis of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14166?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=related_link\">",
"      Intestinal tapeworms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22357?source=related_link\">",
"      Microbiology and epidemiology of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=related_link\">",
"      Pasteurella infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=related_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=related_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=related_link\">",
"      Toxocariasis: visceral and ocular larva migrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=related_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29066="Management of rosacea";
var content_f28_24_29066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of rosacea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Lisa E Maier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/24/29066/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/24/29066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2324120\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is a chronic and relapsing inflammatory skin disorder that primarily involves the central face. Common clinical features include facial erythema, telangiectasias, and inflammatory skin lesions. Many patients seek therapy due to concern over the effect of rosacea on physical appearance. As there is no cure for rosacea, treatment is focused on symptom suppression.",
"   </p>",
"   <p>",
"    The management of rosacea will be discussed here. The pathogenesis and clinical features of rosacea are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324127\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is divided into four subtypes which are defined by the presence of specific clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/1\">",
"     1",
"    </a>",
"    ]. Identification of the disease subtype and severity of involvement are essential for the selection of appropriate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subtypes of rosacea include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Erythematotelangiectatic rosacea:",
"      </strong>",
"      Features of erythematotelangiectatic rosacea include transient facial erythema (flushing), centrofacial nontransient erythema, telangiectasias, skin sensitivity, edema, and a dry or scaly skin texture (",
"      <a class=\"graphic graphic_picture graphicRef77020 graphicRef56083 \" href=\"UTD.htm?23/52/24391\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H394012146#H394012146\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Erythematotelangiectatic rosacea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Papulopustular rosacea:",
"      </strong>",
"      Patients with papulopustular rosacea present with inflammatory papules and pustules on the central face. In addition, persistent erythema, telangiectasias, flushing, and other features of erythematotelangiectatic rosacea may occur in patients with papulopustular disease (",
"      <a class=\"graphic graphic_picture graphicRef67890 graphicRef78747 \" href=\"UTD.htm?7/12/7368\">",
"       picture 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H432928#H432928\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Papulopustular rosacea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Phymatous rosacea:",
"      </strong>",
"      Phymatous rosacea is characterized by skin and sebaceous hypertrophy that results in distortion of facial contours. Severe disfigurement may occur (",
"      <a class=\"graphic graphic_picture graphicRef61822 \" href=\"UTD.htm?0/32/514\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H394012163#H394012163\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Phymatous rosacea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ocular rosacea:",
"      </strong>",
"      A variety of ocular findings may occur in rosacea, including conjunctival hyperemia, anterior blepharitis, keratitis, lid margin telangiectasias, abnormal tearing, cicatricial conjunctivitis, and chalazion or hordeolum (stye) formation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H394012175#H394012175\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Ocular rosacea'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features of more than one subtype of rosacea may occur simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324134\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions may be useful for the management of the cutaneous manifestations of rosacea, regardless of clinical subtype. These include avoidance of triggers of flushing, gentle skin care, sun-protection, and the use of cosmetic products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324141\">",
"    <span class=\"h2\">",
"     Avoidance of flushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Easy flushing is a common feature of rosacea that may occur in all subtypes, particularly in the setting of erythematotelangiectatic or papulopustular disease. Flushing is a prominent and troubling symptom for some patients, and some authors have proposed that flushing may contribute to worsening of other features of rosacea, such as inflammatory papules, erythema, and skin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential triggers for flushing include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extremes of temperature",
"     </li>",
"     <li>",
"      Sunlight",
"     </li>",
"     <li>",
"      Spicy foods",
"     </li>",
"     <li>",
"      Alcohol",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Acute psychological stressors",
"     </li>",
"     <li>",
"      Medications",
"     </li>",
"     <li>",
"      Menopausal hot flashes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individual patients may also have unique triggers for flushing, and the degree of flushing in response to the above stimuli is variable. Thus, asking patients to keep a diary of flushing episodes and potential associated factors can be useful for identifying and avoiding pertinent triggers. In addition, practical measures to reduce flushing after encounters with stimuli, such as applying cool compresses and transferring to cool environments, may be helpful.",
"   </p>",
"   <p>",
"    A variety of pharmacologic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , beta-blockers, antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    have been used in attempts to reduce flushing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. However, data are limited on their efficacy in rosacea and no single therapy appears to be consistently effective. Moreover, the potential for drug-related adverse effects must be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link&amp;anchor=H28#H28\">",
"     \"Approach to flushing in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser, intense pulsed light, and photodynamic therapy also have been used for patients with rosacea-related flushing, but data are limited on treatment effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324148\">",
"    <span class=\"h2\">",
"     Skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rosacea, particularly those with the erythematotelangiectatic subtype, can experience heightened sensitivity of facial skin characterized by difficulty tolerating topical cosmetics, skin care products, and topical medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, rough, dry, or scaly facial skin is a common feature of erythematotelangiectatic rosacea.",
"   </p>",
"   <p>",
"    It is unclear whether subjective skin sensitivity and dryness result from abnormalities in skin barrier function that precede the development of rosacea, or whether they occur as a consequence of the inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/21\">",
"     21",
"    </a>",
"    ]. Regardless, gentle skin care practices may help to reduce symptoms. Appropriate measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Frequent skin moisturization &ndash;",
"      </strong>",
"      Emollients help to repair and maintain cutaneous barrier function and may be useful in rosacea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In a 15-day split-face study of 20 patients with erythematotelangiectatic rosacea treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      0.75% gel, concomitant application of a moisturizing cream twice daily was associated with a significant reduction in experimentally-induced symptoms of skin sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/23\">",
"       23",
"      </a>",
"      ]. Relatively greater reductions in scores of skin dryness, roughness, and discomfort were also detected.",
"     </li>",
"     <li>",
"      <strong>",
"       Gentle skin cleansing &ndash;",
"      </strong>",
"      Patients should be instructed to cleanse their skin gently with lukewarm water, to wash with their fingers, and to avoid harsh mechanical scrubbing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/20,24\">",
"       20,24",
"      </a>",
"      ]. Non-soap cleansers with synthetic detergents (eg, beauty bars, mild cleansing bars, many liquid facial cleansers) are usually better tolerated than traditional soaps. The latter are alkaline which may raise the pH of the skin to abnormal levels and impair skin barrier function [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/25\">",
"       25",
"      </a>",
"      ]. In contrast, synthetic detergent cleansers typically have a pH that more closely approximates the normal pH of the skin (skin pH = 4.0 to 6.5).",
"     </li>",
"     <li>",
"      <strong>",
"       Avoidance of irritating topical products &ndash;",
"      </strong>",
"      Patients should avoid topical products that may irritate the skin, such as toners, astringents, and chemical exfoliating agents (eg, alpha hydroxy acids) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Manual exfoliation with rough sponges or cloths also should be avoided. Skin care products in the form of powders or creams are generally better tolerated than gels and thin lotions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, cosmetics should be easy to remove to avoid the need for harsh cleansing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324155\">",
"    <span class=\"h2\">",
"     Sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of sun exposure in the pathogenesis of rosacea is uncertain. Flares of facial redness and flushing may be stimulated by exposure to radiant heat from the sun, and ultraviolet radiation may induce cutaneous changes that promote rosacea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433400#H433400\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Ultraviolet radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We routinely recommend daily application of a broad-spectrum sunscreen with a sun protection factor (SPF) of at least 30, and educate patients on mid-day sun avoidance and the use of sun-protective clothing. Sunscreens in the form of creams, lotions, or preparations that contain barrier protective silicones (eg, dimethicone or cyclomethicone) are preferred over those in an alcohol-based vehicle, which may be more likely to cause irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324162\">",
"    <span class=\"h2\">",
"     Cosmetic camouflage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For female patients who are bothered by facial erythema or telangiectasias, green-tinted foundation can help to camouflage these features. A flesh-colored facial foundation should be applied on top of the green-tinted foundation to achieve a color that matches the patient&rsquo;s complexion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/28\">",
"     28",
"    </a>",
"    ]. For men, light application of a green-tinted cosmetic facial powder can be useful for camouflaging facial redness. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324935\">",
"    <span class=\"h1\">",
"     ERYTHEMATOTELANGIECTATIC ROSACEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythematotelangiectatic rosacea is characterized by persistent centrofacial erythema, telangiectasias, flushing, skin dryness, skin sensitivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    facial edema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H394012146#H394012146\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Erythematotelangiectatic rosacea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324942\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic measures may assist with reducing facial redness, flushing, skin sensitivity, and skin dryness, and are sufficient for the management of some patients with mild symptoms. When satisfactory improvement cannot be attained with these interventions, treatment with lasers, intense pulsed light, or pharmacologic agents is an option. The treatment of flushing is challenging; the management of this feature is discussed in greater detail elsewhere. (See",
"    <a class=\"local\" href=\"#H2324141\">",
"     'Avoidance of flushing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=see_link&amp;anchor=H28#H28\">",
"     \"Approach to flushing in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324949\">",
"    <span class=\"h3\">",
"     First-line interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral changes can be beneficial in patients with erythematotelangiectatic rosacea. We educate all patients on the avoidance of triggers of flushing, proper use of sun protection, and gentle skin care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2324134\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2324956\">",
"    <span class=\"h3\">",
"     Second-line interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to improve adequately with behavioral interventions and who desire additional treatment may benefit from medical intervention. Options include light-based modalities and multiple pharmacologic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696617\">",
"    <span class=\"h4\">",
"     Laser and intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser and light-based therapies, which have been used extensively for the treatment of a variety of vascular lesions, have also been used for the vascular features of rosacea, especially telangiectasias. During treatment, light energy is absorbed by hemoglobin in cutaneous vessels, leading to vessel heating and coagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H12728454#H12728454\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular lesions are commonly treated with lasers that emit green or yellow light (eg, pulsed dye or potassium titanyl phosphate [KTP] lasers) due to the relatively high absorption of light in these ranges by hemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"UTD.htm?21/34/22048\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72989 \" href=\"UTD.htm?31/7/31869\">",
"     table 1",
"    </a>",
"    ). Intense pulsed light devices, which are also frequently used for this indication, are lower energy light sources that emit noncoherent light in a broad range of wavelengths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H12728466#H12728466\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Vascular lasers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in both facial erythema and telangiectasias can occur after treatment with pulsed dye lasers, KTP lasers, or intense pulsed light [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/16,29-42\">",
"     16,29-42",
"    </a>",
"    ]. Most data on the efficacy of these modalities are derived from uncontrolled studies. One split-face randomized trial compared treatment with a pulsed dye laser with nonpupuragenic settings to intense pulsed light and no treatment in 29 patients with erythematotelangiectatic rosacea. The two therapies were similarly beneficial for facial erythema and telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061370#H10061370\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Telangiectasias and the red face'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Near infrared lasers can be used to treat large, deep telangiectasias, but are associated with increased risk for adverse effects (",
"    <a class=\"graphic graphic_table graphicRef72989 \" href=\"UTD.htm?31/7/31869\">",
"     table 1",
"    </a>",
"    ). Improvement in other clinical features, such as flushing, skin sensitivity, and skin texture have also been reported in patients treated with laser or intense pulsed light therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/16,18,43\">",
"     16,18,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Light-based modalities do not cure rosacea, and periodic treatments to maintain improvement are often required. Potential adverse effects of laser and intense pulsed light therapy include skin dyspigmentation, blistering, ulceration, and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H501291\">",
"    <span class=\"h4\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of treatment with light-based modalities may be prohibitive for some patients. Data from studies in patients with papulopustular rosacea suggest that medications primarily used for papulopustular disease (eg, topical antimicrobials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , and oral antibiotics) may also have benefit for the reduction of rosacea-associated facial erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/44-52\">",
"     44-52",
"    </a>",
"    ]. However, no high quality randomized trials have evaluated efficacy in patients with exclusively erythematotelangiectatic disease. In our experience, satisfactory improvement in persistent facial erythema with these agents is uncommon. Telangiectasias are particularly unlikely to improve with medications, and are best managed with light-based treatments (see",
"    <a class=\"local\" href=\"#H696617\">",
"     'Laser and intense pulsed light'",
"    </a>",
"    above). &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"     Brimonidine",
"    </a>",
"    tartrate, a vasoconstrictive alpha adrenergic receptor agonist used in the treatment of open angle glaucoma, has emerged as a potential treatment for rosacea-associated facial erythema. The efficacy of this agent when applied topically is supported by the results of two phase II randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/53\">",
"     53",
"    </a>",
"    ]. Brimonidine tartrate is not yet commercially available in a formulation specifically for cutaneous use. Further investigations are necessary to determine the role of brimonidine tartrate in the treatment of rosacea.",
"   </p>",
"   <p>",
"    Additional studies are also required to determine the value of topical retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], licochalcone A (an ingredient derived from the licorice plant that is present in Eucerin",
"    <sup>",
"     &reg;",
"    </sup>",
"    Redness Relief) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/56\">",
"     56",
"    </a>",
"    ], oral isotretinoin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/26\">",
"     26",
"    </a>",
"    ], and topical oxymetazoline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/57\">",
"     57",
"    </a>",
"    ] (an alpha adrenergic receptor agonist primarily used for nasal congestion that reduced facial erythema and flushing in two patients) in the treatment of erythematotelangiectatic rosacea. The role of topical calcineurin inhibitors (tacrolimus and pimecrolimus) in erythematotelangiectatic rosacea is uncertain. Improvement with topical tacrolimus has been reported in small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the reduction of facial erythema in patients with papulopustular rosacea are reviewed below (see",
"    <a class=\"local\" href=\"#H2325345\">",
"     'Papulopustular rosacea'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325345\">",
"    <span class=\"h1\">",
"     PAPULOPUSTULAR ROSACEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papulopustular rosacea is characterized by inflammatory papules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pustules primarily distributed on the central face. Patients often also exhibit features of erythematotelangiectatic rosacea, such as persistent facial erythema, frequent flushing, and telangiectasias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325353\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with mild to moderate disease (",
"    <a class=\"graphic graphic_picture graphicRef59815 graphicRef53889 \" href=\"UTD.htm?38/57/39832\">",
"     picture 4A-B",
"    </a>",
"    ) can be managed with topical therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur. Systemic agents are typically used in patients who fail to respond satisfactorily to topical agents or who present with numerous inflammatory lesions (",
"    <a class=\"graphic graphic_picture graphicRef78747 \" href=\"UTD.htm?6/54/7011\">",
"     picture 2B",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    -class antibiotics are first-line systemic agents for papulopustular rosacea; for patients who fail to respond to tetracyclines or who cannot tolerate these drugs, treatment with other oral antibiotics is an option. Laser therapy, intense pulsed light, and photodynamic therapy have also been used in papulopustular rosacea, but the efficacy of these therapies remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325879\">",
"    <span class=\"h3\">",
"     Mild to moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    are considered first-line therapies in mild to moderate disease (",
"    <a class=\"graphic graphic_picture graphicRef59815 graphicRef53889 \" href=\"UTD.htm?38/57/39832\">",
"     picture 4A-B",
"    </a>",
"    ) due to evidence from randomized trials in support of their efficacy and the relative safety of these medications. Other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur, also may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325366\">",
"    <span class=\"h4\">",
"     Topical metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism through which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    improves rosacea is unknown, but may involve antimicrobial, antiinflammatory, or antioxidant properties [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/60\">",
"     60",
"    </a>",
"    ]. Topical metronidazole is most effective for the treatment of inflammatory papules and pustules, but may also contribute to improvement in facial erythema.",
"   </p>",
"   <p>",
"    A systematic review of randomized trials performed primarily in patients with papulopustular rosacea supported the use of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/61\">",
"     61",
"    </a>",
"    ]. Metronidazole was superior to placebo (relative risk [RR] 1.95; 95% CI 1.48-2.56).",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is available as a 0.75% cream or gel, a 1% cream or gel, and a 0.75% lotion. Unlike 1% formulations, which are labeled for once-daily application, drug labels for 0.75% formulations recommend twice daily use. However, the product concentration, frequency of application, and vehicle (cream, gel, or lotion) may not significantly affect treatment efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 12-week single-blind randomized trial that compared once daily application of 0.75% cream to once daily application of 1% cream in 72 patients with papulopustular rosacea, no significant difference in the percent reduction in median inflammatory lesion counts (62 versus 60 percent) or erythema scores (26 versus 30 percent) was detected [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from a meta-analysis of randomized placebo-controlled trials were insufficient to draw definitive conclusions on the relative efficacy of once versus twice daily dosing [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Randomized trials comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      0.75% cream versus 0.75% gel and 0.75% gel versus 0.75% lotion have found similar treatment efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/61,63\">",
"       61,63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data above suggests that once daily application of 0.75%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    may be sufficient, but additional studies are necessary. The drug vehicle should be selected based upon patient preference and tolerability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of acne vulgaris\", section on 'Choice of vehicles for topical treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in inflammatory lesions may occur after as few as two to four weeks of therapy, but full results are typically observed after eight to nine weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. Relapses often occur when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is discontinued; thus, long-term therapy is usually needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is generally well-tolerated; the most common adverse effects are local irritation, dryness, and stinging sensations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325386\">",
"    <span class=\"h4\">",
"     Topical azelaic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    is a naturally occurring dicarboxylic acid with antiinflammatory and antioxidative properties. Similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , azelaic acid improves papular and pustular lesions, and may also reduce erythema.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    is available as a 20% cream or lotion, or as a 15% gel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/69\">",
"     69",
"    </a>",
"    ]. Only the cream and gel formulations are available in the United States.",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    for rosacea is supported by a systematic review of randomized trials performed primarily in patients with papulopustular rosacea. Azelaic acid was a more effective treatment than placebo (RR 1.52, 95% CI 1.32 to 1.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/61\">",
"     61",
"    </a>",
"    ]. Examples of trials demonstrating efficacy of this agent include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two 12-week vehicle-controlled randomized trials with a total of 664 patients with papulopustular rosacea found significantly greater mean reductions in inflammatory lesions in patients treated with twice daily applications of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      15% gel than in the vehicle group (58 versus 40 percent and 51 versus 39 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/45\">",
"       45",
"      </a>",
"      ]. Patients in the active treatment group were also more likely to exhibit improvement in erythema (44 versus 29 percent and 46 versus 28 percent, respectively). Facial telangiectasias did not respond to therapy.",
"     </li>",
"     <li>",
"      A three-month vehicle-controlled randomized trial in 116 patients with papulopustular rosacea found that twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      20% cream led to superior mean percent reductions in inflammatory lesion counts (73 versus 50 percent) and erythema severity scores (48 versus 38 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial improvement from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    may be noted within the first few weeks of use. Better results are typically observed after 12 to 15 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although package inserts for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    recommend twice daily application, a randomized trial in 72 patients treated with the 15% gel failed to identify a difference in efficacy between once daily and twice daily dosing, suggesting that once daily application may be sufficient for improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/71\">",
"     71",
"    </a>",
"    ]. Rates of adverse effects and treatment tolerability were similar in the two groups.",
"   </p>",
"   <p>",
"    The most frequent side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    is skin discomfort after application [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/70,72,73\">",
"     70,72,73",
"    </a>",
"    ]. In two randomized trials in which a total of 333 patients were treated with azelaic acid 15% gel, 38 percent of patients reported burning, itching, or stinging sensations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/45\">",
"     45",
"    </a>",
"    ]. Symptoms were transient and mild to moderate in the majority of patients, and less than 1 percent of all patients had severe, persistent sensory symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16743134\">",
"    <span class=\"h5\">",
"     Azelaic acid versus metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     Azelaic acid",
"    </a>",
"    appears to be at least equally as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for the treatment of papulopustular rosacea and some trials have demonstrated superior efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest randomized trial (n = 251) comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      in patients with papulopustular rosacea found that twice daily application of azelaic acid 15% gel for up to 15 weeks was superior to twice daily application metronidazole 0.75% gel [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/67\">",
"       67",
"      </a>",
"      ]. Azelaic acid was associated with significantly greater mean reductions in inflammatory lesion counts (73 versus 56 percent with metronidazole) and a higher rate of improvement in erythema (56 versus 42 percent of patients).",
"     </li>",
"     <li>",
"      A 15-week investigator-blinded randomized trial in 160 patients that compared twice daily applications of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      15% gel to once daily applications of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      1% gel found similar improvements in inflammatory lesion counts and erythema [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 15-week split-face randomized trial (n =40) in which twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      20% cream was compared with twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      0.75% cream found similar improvements with the two preparations in inflammatory lesions, erythema, and skin dryness, and no difference in burning sensations related to rosacea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/46\">",
"       46",
"      </a>",
"      ]. Stinging sensations associated with drug application were more frequent in patients treated with azelaic acid.",
"     </li>",
"     <li>",
"      A randomized trial (n =24) comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      20% cream,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      0.75% cream, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      5% cream found that azelaic acid was superior to the other therapies for the treatment of inflammatory lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/75\">",
"       75",
"      </a>",
"      ]. The three agents had similar benefit for erythema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    are reasonable choices for first-line topical therapy for papulopustular rosacea. The lower cost of metronidazole 0.75% gel (the least expensive formulation of metronidazole) compared with azelaic acid favors the initial use of metronidazole. We also favor metronidazole in patients who present with significant facial sensitivity, due to the fairly frequent occurrence of irritation early in the course of therapy with azelaic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/70,72,73\">",
"     70,72,73",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2325386\">",
"     'Topical azelaic acid'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16742896\">",
"    <span class=\"h4\">",
"     Alternative topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less well-studied topical agents used for the management of rosacea include topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , topical retinoids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    . We generally utilize these agents in patients who cannot tolerate or obtain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , or who fail to respond to those therapies but prefer to avoid oral agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325624\">",
"    <span class=\"h5\">",
"     Sulfacetamide-sulfur",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    -sulfur is available in a variety of formulations, including topical suspensions, lotions, cleansers, creams, foams, and cleansing pads. The most common concentration is sulfacetamide 10% with sulfur 5%. Other drug concentrations and formulations with added sunscreen or cosmetically-beneficial green coloring are also available (see",
"    <a class=\"local\" href=\"#H2324162\">",
"     'Cosmetic camouflage'",
"    </a>",
"    above). The mechanism of action of sulfacetamide-sulfur in rosacea is unknown.",
"   </p>",
"   <p>",
"    In comparison to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    , data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur is limited. A vehicle-controlled randomized trial in 103 patients and an open-label study in 59 patients reported benefit of this agent for inflammatory lesions and erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Additional studies are necessary to confirm the results of a 12-week randomized trial of 152 patients that found that a sulfacetamide 10%-sulfur 5% cream containing sunscreen was superior to metronidazole 0.75% cream for the reduction of pustular, but not papular, lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur include local irritation and allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/26,76\">",
"     26,76",
"    </a>",
"    ]. Use of sulfacetamide-sulfur should be avoided in patients with sulfonamide (&ldquo;sulfa&rdquo;) allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/26\">",
"     26",
"    </a>",
"    ]. Of note, some patients find the odor of sulfacetamide-sulfur agents unfavorable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25403012\">",
"    <span class=\"h5\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Other topical antimicrobials &ndash;",
"      </strong>",
"      In a 12-week randomized trial of 53 patients with papulopustular rosacea, a gel containing a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"       benzoyl peroxide",
"      </a>",
"      5% and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      1% was superior to vehicle for the reduction of papulopustules (mean percent reduction 71 versus 19 percent), erythema, and",
"      <span class=\"nowrap\">",
"       flushing/blushing",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/48\">",
"       48",
"      </a>",
"      ]. Monotherapy with clindamycin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      may also be beneficial; clindamycin lotion was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      in one randomized trial of 43 patients with papulopustular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/47\">",
"       47",
"      </a>",
"      ], and erythromycin solution was associated with improvement in papulopustules and erythema in an open-label study of 15 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Topical retinoids &ndash;",
"      </strong>",
"      Topical retinoids have antiinflammatory and extracellular matrix repair properties, and may be beneficial for patients with rosacea. In a randomized trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"       adapalene",
"      </a>",
"      0.1% gel to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      0.75% gel in 55 patients with papulopustular rosacea, adapalene was associated with significantly greater reductions in inflammatory lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/80\">",
"       80",
"      </a>",
"      ]. Unlike metronidazole, adapalene did not induce significant improvement in erythema. Tretinoin 0.025% cream has also been used for the treatment of rosacea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/54\">",
"       54",
"      </a>",
"      ]. The potential for drug-induced skin irritation must be considered when prescribing topical retinoids.",
"     </li>",
"     <li>",
"      <strong>",
"       Permethrin",
"      </strong>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Although a causal relationship between Demodex mites and rosacea is uncertain, topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      , an antiparasitic agent, may have benefit for the treatment of rosacea. In a randomized trial of 63 patients with papulopustular rosacea that compared treatment with permethrin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      gel, and placebo, improvement with permethrin was equivalent to metronidazole and superior to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/81\">",
"       81",
"      </a>",
"      ]. The validity of these results may be questionable due to the close clinical resemblance of Demodex folliculitis to rosacea. The safety of long-term permethrin use also is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433276#H433276\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Demodex'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H2005723#H2005723\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Papulopustular rosacea'",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical calcineurin inhibitors do not appear to be beneficial for papulopustular rosacea. Small placebo controlled randomized trials failed to find statistically superior efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment was not effective for papulopustular lesions in a small uncontrolled study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, the development of rosacea-like cutaneous eruptions has been reported in patients treated with topical tacrolimus for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325908\">",
"    <span class=\"h3\">",
"     Moderate to severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with numerous inflammatory papules or pustules (",
"    <a class=\"graphic graphic_picture graphicRef78747 \" href=\"UTD.htm?6/54/7011\">",
"     picture 2B",
"    </a>",
"    ), or those with milder disease that fails to respond to one or more topical therapies may benefit from oral antibiotic therapy. Tetracyclines are the best studied agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2325871\">",
"    <span class=\"h4\">",
"     Oral tetracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    have been used for many years for the management of papulopustular rosacea. These agents are most useful for improving inflammatory papules and pustules, and may also reduce erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since no definitive microbial cause of rosacea has been identified, the efficacy of oral antibiotics in rosacea is often attributed to their antiinflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/85\">",
"     85",
"    </a>",
"    ]. Tetracyclines may decrease levels of proinflammatory cathelicidins (components of the innate immune system) through inhibition of serine proteases, may reduce levels of proinflammatory cytokines, and may have matrix-protecting capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433190#H433190\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Immune dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264219\">",
"    <span class=\"h5\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional, antimicrobial doses for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    are 250 mg to 1000 mg per day and 100 to 200 mg per day for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Few placebo-controlled randomized trials have evaluated the efficacy of these doses in rosacea. In two early, small trials, tetracycline (250 mg twice daily for four to eight weeks or 750 mg per day for one week followed by 250 mg to 500 mg per day for five weeks) was associated with improvement in inflammatory lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/49,89\">",
"     49,89",
"    </a>",
"    ]. In addition, randomized trials comparing doxycycline to other oral antibiotics found that a 100 mg per day dose of doxycycline effectively improves papulopustular rosacea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/52,90\">",
"     52,90",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2326144\">",
"     'Alternative oral antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Due to concern for the development of antibiotic resistance, interest has grown in the use of subantimicrobial doses of antibiotics, which retain antiinflammatory properties but lack antibacterial effects. Support for the efficacy of subantimicrobial doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (20 mg taken twice daily or a combination pill containing 30 mg of immediate release doxycycline and 10 mg of delayed release doxycycline taken once daily) come from both randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/91,92\">",
"     91,92",
"    </a>",
"    ] and an open label study of almost 1200 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/51\">",
"     51",
"    </a>",
"    ]. In two 16-week placebo-controlled randomized trials performed in 537 patients with 10 to 40 inflammatory lesions, doxycycline was associated with significantly greater reductions in inflammatory lesion counts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/91\">",
"     91",
"    </a>",
"    ]. In addition, one of the two trials and the open-label study found improvement in erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized trials have compared subantimicrobial dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    to a 100 mg twice daily dose or to traditional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    . One randomized trial with 91 patients compared subantimicrobial dose doxycycline (40 mg once daily) with doxycycline 100 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/93\">",
"     93",
"    </a>",
"    ]. Both doses were similarly effective for the treatment of inflammatory lesions, but the lower dose was associated with a reduced rate of gastrointestinal side effects (5 versus 26 percent).",
"   </p>",
"   <p>",
"    We typically initiate treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    50 to 100 mg twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    50 to 100 mg twice daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    250 to 500 mg twice daily and continue treatment for 4 to 12 weeks in an attempt to quickly decrease inflammation. Initiating treatment with subantimicrobial dose doxycycline is another reasonable option.",
"   </p>",
"   <p>",
"    After satisfactory improvement is attained with the initial course of therapy, we transition patients to a topical agent, most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H2325366\">",
"     'Topical metronidazole'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2325386\">",
"     'Topical azelaic acid'",
"    </a>",
"    above). Continuing oral therapy at the lowest effective dose is another option in patients who fail to maintain improvement or who are unable to tolerate topical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/2\">",
"     2",
"    </a>",
"    ]. Subantimicrobial dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is our preferred choice for long-term oral therapy.",
"   </p>",
"   <p>",
"    Patients who respond well to topical maintenance therapy may have occasional &ldquo;break-through&rdquo; flares of papulopustular lesions spaced by several months or more. For such patients, we have found the administration of an abbreviated course of an oral antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    500 mg twice daily for 10 days) useful for quieting the acute flares, circumventing the need for long-term oral therapy. These patients are continued on topical maintenance therapy during and after oral treatment.",
"   </p>",
"   <p>",
"    Adverse effects of oral tetracyclines include gastrointestinal distress and photosensitivity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    is the least photosensitizing of these agents, but it may cause vertigo, a lupus-like syndrome, and skin discoloration. Tetracyclines should",
"    <strong>",
"     not",
"    </strong>",
"    be given to children under the age of nine due to a risk for permanent tooth discoloration and reduced bone growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689662\">",
"    <span class=\"h5\">",
"     Combined with topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding an oral antibiotic to topical therapy may improve treatment results. Two randomized trials that compared treatment with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    alone to topical metronidazole plus subantimicrobial dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    found superior improvement in inflammatory lesions with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/92,94\">",
"     92,94",
"    </a>",
"    ]. Additional trials are necessary to determine whether combination therapy has advantages over monotherapy with an oral antibiotic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2326144\">",
"    <span class=\"h4\">",
"     Alternative oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other oral antibiotics are less frequently used for the treatment of rosacea, but may also be effective. These include macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/26,50,52,90\">",
"     26,50,52,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An eight-week randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (250 mg twice daily for four weeks followed by 250 mg daily for four weeks) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily for four weeks followed by 100 mg once daily for four weeks) found significantly greater improvement in objective measures of inflammatory lesions, erythema, and telangiectasias in patients treated with clarithromycin at early study time points, but differences among the two groups dissipated by week eight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/52\">",
"     52",
"    </a>",
"    ]. A separate 12-week trial that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (500 mg three times per week followed by a taper) to doxycycline 100 mg daily found that the drugs were similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is commonly used for the treatment of rosacea in Europe. In a randomized trial of 40 patients that compared treatment with metronidazole (200 mg twice daily) to oxytetracycline (250 mg twice daily), the agents appeared to be similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/95\">",
"     95",
"    </a>",
"    ]. Alcohol should be avoided during treatment with metronidazole due to the possibility of the induction of a disulfiram-like reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693879\">",
"    <span class=\"h3\">",
"     Refractory disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H693795\">",
"    <span class=\"h4\">",
"     Oral isotretinoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to respond to topical therapies and oral antibiotics may improve with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/54,96-98\">",
"     54,96-98",
"    </a>",
"    ]. Oral isotretinoin is not used as first-line therapy due to the drug&rsquo;s many adverse effects, including teratogenicity. In the United States, oral isotretinoin can only be prescribed through the",
"    <a class=\"external\" href=\"https://www.ipledgeprogram.com/\">",
"     iPLEDGE program",
"    </a>",
"    , an internet-based risk management program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H8#H8\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Teratogenicity and the iPLEDGE program'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although improvement in inflammatory lesions and facial erythema has been reported in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/54,96-98\">",
"     54,96-98",
"    </a>",
"    ], high quality data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    for rosacea are lacking, and the ideal regimen for treatment has not been established. Doses of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day have been utilized in some patients, but lower doses may be effective and better-tolerated. The authors of a 12-week dose-comparison trial reported a 90 percent reduction of inflammatory lesions in patients treated with 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/98\">",
"     98",
"    </a>",
"    ]. Additionally, compared with patients who were treated with 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    these patients had a lower incidence of drug-related facial dermatitis.",
"   </p>",
"   <p>",
"    We typically treat patients with around 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (usually a total of 10 to 20 mg per day) until the inflammatory component is consistently well-controlled for one to two months. In our experience, this usually occurs after five to six months of therapy.",
"   </p>",
"   <p>",
"    The longevity of treatment effect varies; in a series of 20 patients with severe rosacea treated with doses of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three to six months, remissions lasting at least one year were reported in 17 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/99\">",
"     99",
"    </a>",
"    ]. Of note, five out of six patients initially treated with 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day required dose reductions due to adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25403507\">",
"    <span class=\"h3\">",
"     Laser and intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with light-based therapies has yielded variable results in patients with papulopustular rosacea. Although the results of two uncontrolled studies utilizing intense pulsed light or pulsed dye laser suggest that some improvement in inflammatory papules is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/100,101\">",
"     100,101",
"    </a>",
"    ], other studies have found conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/34,102,103\">",
"     34,102,103",
"    </a>",
"    ], and there is insufficient evidence to conclude that improvement is long-lasting.",
"   </p>",
"   <p>",
"    Photodynamic therapy, which involves the application of a photosensitizing agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    &nbsp;or methyl aminolevulinic acid) to skin and exposure of the treatment site to a light source, has also yielded mixed results. Improvement in inflammatory lesions lasting three months or longer was reported in a small retrospective study and two out of four patients in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]; however, in another case series, disease severity returned to baseline in three out of four patients within 12 weeks after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689748\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because rosacea is a chronic disorder and treatments for papulopustular rosacea are not curative, continued therapy is typically necessary to maintain treatment response. Most commonly, long term topical therapy is administered. Subantimicrobial doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    are also an option. (See",
"    <a class=\"local\" href=\"#H2325871\">",
"     'Oral tetracyclines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695717\">",
"    <span class=\"h1\">",
"     OCULAR ROSACEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular rosacea may occur in the presence or absence of cutaneous manifestations. Examples of features of ocular rosacea include foreign body sensations, blepharitis, lid margin telangiectasia, tear abnormalities, meibomian gland inflammation, frequent chalazion, conjunctivitis, and rarely, corneal ulcers and vascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/106\">",
"     106",
"    </a>",
"    ]. Patients who present with signs or symptoms of ocular rosacea should be referred to an ophthalmologist for further evaluation.",
"   </p>",
"   <p>",
"    Lid scrubs and warm compresses may help improve meibomian gland function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/107\">",
"     107",
"    </a>",
"    ], and topical antibiotics such as topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    may quell mild lid inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/106,108,109\">",
"     106,108,109",
"    </a>",
"    ]. For those with more moderate to severe ocular rosacea, short courses of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -class antibiotics, macrolide antibiotics, or metronidazole are often needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/108,110,111\">",
"     108,110,111",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may also minimize inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694796\">",
"    <span class=\"h1\">",
"     PHYMATOUS ROSACEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue hypertrophy, dilated follicles, and irregular nodular overgrowths are characteristic features of the phymatous subtype of rosacea. These changes most commonly affect the nose (rhinophyma), but may also affect other areas such as the chin, cheeks, and ears (",
"    <a class=\"graphic graphic_picture graphicRef61822 \" href=\"UTD.htm?0/32/514\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/6,113\">",
"     6,113",
"    </a>",
"    ]. Features of other subtypes of rosacea may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H394012163#H394012163\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Phymatous rosacea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694836\">",
"    <span class=\"h2\">",
"     Early disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach to the treatment of early phymatous rosacea is unknown. Improvements in phymatous changes have been reported in patients treated with 0.3 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    administered for periods of 12 to 28 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/98,114\">",
"     98,114",
"    </a>",
"    ]. The duration of benefit is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H694922\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser ablation and surgical techniques can be used to debulk and recontour tissue distorted by phymatous changes. Ablative carbon dioxide lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/115\">",
"     115",
"    </a>",
"    ] and infrared diode lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/116,117\">",
"     116,117",
"    </a>",
"    ] have been used for this purpose. Surgical debulking can be performed through dermabrasion, scalpel excision, electrosurgery, or cryosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential side effects of laser and surgical interventions include hypopigmentation, scarring, and pain. The risk for pigmentary changes rises with increasing skin pigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695009\">",
"    <span class=\"h1\">",
"     SPECIAL CASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695168\">",
"    <span class=\"h2\">",
"     Granulomatous rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous rosacea may be a variant of rosacea. It presents with uniform red-brown or yellow-brown papules on the face. Other manifestations of rosacea may or may not be present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/1,120,121\">",
"     1,120,121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433591#H433591\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Granulomatous rosacea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efficacy data on treatment for granulomatous rosacea are limited to case reports. Treatments are similar to those used for papulopustular rosacea. However, lesions may be slower to respond or less-likely to respond to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/122,123\">",
"     122,123",
"    </a>",
"    ], and oral antibiotic therapy is often required [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. Successful treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    , and intense pulsed light has also been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/125-129\">",
"     125-129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695001\">",
"    <span class=\"h2\">",
"     Pediatric rosacea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, rosacea develops in children. All subtypes, except for phymatous rosacea may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H433610#H433610\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Pediatric rosacea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with adults, nonpharmacologic measures aimed at reducing symptoms are recommended. Mild to moderate papulopustular disease is usually managed with topical agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"     azelaic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    -sulfur, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H2325879\">",
"     'Mild to moderate disease'",
"    </a>",
"    above). Oral antibiotics may be necessary for patients with more severe papulopustular eruptions. Because tetracyclines are contraindicated in children under the age of nine, oral erythromycin (30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    may be substituted as a first line oral agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/122,130\">",
"     122,130",
"    </a>",
"    ]. Oral metronidazole (20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has also been used in the treatment of children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/131\">",
"     131",
"    </a>",
"    ]. As in adults, after oral antibiotics produce a remission, treatment with a topical agent may be used to maintain clearance.",
"   </p>",
"   <p>",
"    Ocular rosacea is managed similarly as in adults, with the exclusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    antibiotic therapy in children under the age of nine. Granulomatous rosacea in the pediatric population may respond to topical or oral antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/122,131\">",
"     122,131",
"    </a>",
"    ]. Several months of treatment may be required for improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695032\">",
"    <span class=\"h2\">",
"     Pyoderma faciale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyoderma faciale (also known as rosacea fulminans) is an unusual eruption that is not officially recognized as a rosacea variant. The disorder is characterized by an abrupt onset of papules and suppurative nodules on the face [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/132\">",
"     132",
"    </a>",
"    ]. Young women are most commonly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/133\">",
"     133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H2149672#H2149672\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Pyoderma faciale (rosacea fulminans)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the treatment of pyoderma faciale is limited to reports of clinical experience. Patients can be managed with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    . Prednisone is often started at 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and tapered over a period of weeks, and isotretinoin is initiated around two weeks after the start of prednisone therapy with low doses of 0.2 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/130,133,134\">",
"     130,133,134",
"    </a>",
"    ]. During the steroid taper, the isotretinoin dose is slowly increased to 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as tolerated. Some authors advocate treating until a cumulative dose of 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    has been attained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/134\">",
"     134",
"    </a>",
"    ]; others believe that isotretinoin can be discontinued once inflammatory lesions have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/133\">",
"     133",
"    </a>",
"    ]. We typically treat until a cumulative dose of 120 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    has been attained, provided treatment is tolerated.",
"   </p>",
"   <p>",
"    Alternatives to the above regimen include initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (1 g per day) along with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper as above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/133,135\">",
"     133,135",
"    </a>",
"    ]. Successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/24/29066/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26656310\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rosacea is a common disorder that presents with a variety of clinical findings. The four main subtypes of rosacea are erythematotelangiectatic rosacea, papulopustular rosacea, ocular rosacea, and phymatous rosacea. The subtype of rosacea determines the approach to treatment. (See",
"      <a class=\"local\" href=\"#H2324127\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General measures to improve symptoms of flushing, erythema, and skin irritation can be beneficial for patients with rosacea. Patients should be educated on the avoidance of triggers of flushing, gentle skin care, and sun protection. Cosmetic camouflage is a useful adjunct for some patients. (See",
"      <a class=\"local\" href=\"#H2324935\">",
"       'Erythematotelangiectatic rosacea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with erythematotelangiectatic rosacea suffer from persistent facial erythema, telangiectasias, flushing, and sensitive skin. Behavioral modification may reduce symptoms. If persistent facial erythema does not improve sufficiently with behavioral changes, we suggest treatment with laser or intense pulse light (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Periodic retreatment is often necessary to maintain improvement. (See",
"      <a class=\"local\" href=\"#H2324935\">",
"       'Erythematotelangiectatic rosacea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cost of treatment of persistent facial erythema in erythematotelangiectatic rosacea with light-based modalities may be prohibitive for some patients; in patients who defer light-based treatment, a trial of pharmacologic therapy is reasonable. For these patients, treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      , or subantimicrobial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      may be attempted. In our experience, satisfactory improvement with these therapies is uncommon.",
"     </li>",
"     <li>",
"      Further studies are necessary to determine the role of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/32/15877?source=see_link\">",
"       brimonidine",
"      </a>",
"      tartrate for facial erythema. Facial telangiectasias are best managed with laser or intense pulsed light therapy. (See",
"      <a class=\"local\" href=\"#H501291\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflammatory papules and pustules characterize the papulopustular subtype of rosacea. For patients with mild to moderate disease, we suggest treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38627?source=see_link\">",
"       azelaic acid",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2325879\">",
"       'Mild to moderate disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with papulopustular rosacea who present with numerous inflammatory lesions or who have milder disease that fails to improve with topical agents, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      for 4 to 12 weeks (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Improvement may be maintained with topical agents or subantimicrobial doxycycline. (See",
"      <a class=\"local\" href=\"#H2325908\">",
"       'Moderate to severe disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H689748\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with refractory papulopustular rosacea may benefit from treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H693879\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular rosacea can result in damage to the ocular tissues. Patients with signs or symptoms of ocular involvement should be referred to an ophthalmologist for further evaluation. (See",
"      <a class=\"local\" href=\"#H695717\">",
"       'Ocular rosacea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Childhood rosacea is managed similarly to rosacea in adults. However, the use of oral tetracyclines should be",
"      <strong>",
"       avoided",
"      </strong>",
"      in children under the age of nine. (See",
"      <a class=\"local\" href=\"#H695001\">",
"       'Pediatric rosacea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/1\">",
"      Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/2\">",
"      Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis 2009; 84:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/3\">",
"      Wilkin J. A role for vascular pathogenic mechanisms in rosacea: implications for patient care. Cutis 2008; 82:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/4\">",
"      Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol 2004; 50:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/5\">",
"      Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/6\">",
"      Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51:327.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.rosacea.org/rr/2002/summer/article_3.php (Accessed on December 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/8\">",
"      Guarrera M, Parodi A, Cipriani C, et al. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982; 272:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/9\">",
"      Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/10\">",
"      Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol 2005; 53:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/11\">",
"      Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/12\">",
"      Brunner RL, Aragaki A, Barnabei V, et al. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause 2010; 17:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/13\">",
"      Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; :CD004923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/14\">",
"      Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea. Arch Dermatol 2011; 147:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/15\">",
"      Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective &beta;-adrenergic blocker. J Am Acad Dermatol 2012; 67:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/16\">",
"      Taub AF, Devita EC. Successful treatment of erythematotelangiectatic rosacea with pulsed light and radiofrequency. J Clin Aesthet Dermatol 2008; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/17\">",
"      Katz B, Patel V. Photodynamic therapy for the treatment of erythema, papules, pustules, and severe flushing consistent with rosacea. J Drugs Dermatol 2006; 5:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/18\">",
"      Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias. J Cosmet Laser Ther 2011; 13:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/19\">",
"      Goldberg DJ. Lasers and light sources for rosacea. Cutis 2005; 75:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/20\">",
"      Wilkin JK. Use of topical products for maintaining remission in rosacea. Arch Dermatol 1999; 135:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/21\">",
"      Dirschka T, Tronnier H, F&ouml;lster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/22\">",
"      Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study. Cutis 2009; 84:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/23\">",
"      Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat 2007; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/24\">",
"      Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg 2001; 20:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/25\">",
"      Draelos ZD. Facial hygiene and comprehensive management of rosacea. Cutis 2004; 73:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/26\">",
"      Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/27\">",
"      Nichols K, Desai N, Lebwohl MG. Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 1998; 61:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/28\">",
"      Draelos ZD. Colored facial cosmetics. Dermatol Clin 2000; 18:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/29\">",
"      Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 2008; 159:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/30\">",
"      Mark KA, Sparacio RM, Voigt A, et al. Objective and quantitative improvement of rosacea-associated erythema after intense pulsed light treatment. Dermatol Surg 2003; 29:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/31\">",
"      Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold. Dermatol Surg 2003; 29:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/32\">",
"      Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/33\">",
"      Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004; 51:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/34\">",
"      Clark SM, Lanigan SW, Marks R. Laser treatment of erythema and telangiectasia associated with rosacea. Lasers Med Sci 2002; 17:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/35\">",
"      Lonne-Rahm S, Nordlind K, Edstr&ouml;m DW, et al. Laser treatment of rosacea: a pathoetiological study. Arch Dermatol 2004; 140:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/36\">",
"      Tan ST, Bialostocki A, Armstrong JR. Pulsed dye laser therapy for rosacea. Br J Plast Surg 2004; 57:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/37\">",
"      Schroeter CA, Haaf-von Below S, Neumann HA. Effective treatment of rosacea using intense pulsed light systems. Dermatol Surg 2005; 31:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/38\">",
"      Maxwell EL, Ellis DA, Manis H. Acne rosacea: effectiveness of 532 nm laser on the cosmetic appearance of the skin. J Otolaryngol Head Neck Surg 2010; 39:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/39\">",
"      Iyer S, Fitzpatrick RE. Long-pulsed dye laser treatment for facial telangiectasias and erythema: evaluation of a single purpuric pass versus multiple subpurpuric passes. Dermatol Surg 2005; 31:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/40\">",
"      Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers? Dermatol Surg 2004; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/41\">",
"      Tanghetti E, Sherr EA, Sierra R, Mirkov M. The effects of pulse dye laser double-pass treatment intervals on depth of vessel coagulation. Lasers Surg Med 2006; 38:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/42\">",
"      Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 2009; 35:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/43\">",
"      Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med 2008; 40:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/44\">",
"      Nielsen PG. A double-blind study of I% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/45\">",
"      Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/46\">",
"      Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/47\">",
"      Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/48\">",
"      Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol 2004; 43:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/49\">",
"      Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/50\">",
"      Bakar O, Demir&ccedil;ay Z, G&uuml;rb&uuml;z O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/51\">",
"      Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis 2010; 86:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/52\">",
"      Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol 1997; 36:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/53\">",
"      Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0&middot;5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol 2012; 166:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/54\">",
"      Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994; 130:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/55\">",
"      Vienne MP, Ochando N, Borrel MT, et al. Retinaldehyde alleviates rosacea. Dermatology 1999; 199 Suppl 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/56\">",
"      Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone A. J Cosmet Dermatol 2006; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/57\">",
"      Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007; 143:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/58\">",
"      Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. J Eur Acad Dermatol Venereol 2009; 23:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/59\">",
"      Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/60\">",
"      Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther 2001; 18:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/61\">",
"      van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2011; :CD003262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/62\">",
"      Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol 2001; 45:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/63\">",
"      Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/64\">",
"      Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol 1987; 123:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/65\">",
"      Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998; 61:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/66\">",
"      Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 2007; 79:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/67\">",
"      Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003; 139:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/68\">",
"      Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/69\">",
"      Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991; 283:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/70\">",
"      Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999; 79:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/71\">",
"      Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 2008; 7:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/72\">",
"      Col&oacute;n LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis 2007; 79:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/73\">",
"      Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol 2005; 4:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/74\">",
"      Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006; 77:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/75\">",
"      Mostafa FF, El Harras MA, Gomaa SM, et al. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol 2009; 23:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/76\">",
"      Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat 1997; 8:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/77\">",
"      Davis GF, Glazer SD, Medansky RS. Successful treatment of rosacea with a novel formulation of sodium sulfacetamide 10% and sulfur 5% (Novacet,) topical lotion. J Geriatr Dermatol 1994; 2:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/78\">",
"      Torok HM, Webster G, Dunlap FE, et al. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005; 75:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/79\">",
"      Mills OH Jr, Kligman AM. Letter: Topically applied erythromycin in rosacea. Arch Dermatol 1976; 112:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/80\">",
"      Altinyazar HC, Koca R, Tekin NS, E��t&uuml;rk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005; 44:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/81\">",
"      Ko&ccedil;ak M, Ya��li S, Vahapo��lu G, Ek��io��lu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology 2002; 205:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/82\">",
"      Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/83\">",
"      Karabulut AA, Izol Serel B, Eksioglu HM. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. J Eur Acad Dermatol Venereol 2008; 22:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/84\">",
"      Fujiwara S, Okubo Y, Irisawa R, Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. J Am Acad Dermatol 2010; 62:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/85\">",
"      Korting HC, Sch&ouml;llmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/86\">",
"      Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/87\">",
"      Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/88\">",
"      Korting HC, Sch&ouml;llmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 2009; 23:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/89\">",
"      Marks R, Ellis J. Comparative effectiveness of tetracycline and ampicillin in rosacea. A controlled trial. Lancet 1971; 2:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/90\">",
"      Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/91\">",
"      Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/92\">",
"      Sanchez J, Somolinos AL, Almod&oacute;var PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005; 53:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/93\">",
"      Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/94\">",
"      Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/95\">",
"      Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/96\">",
"      Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/97\">",
"      Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 1998; 134:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/98\">",
"      Gollnick H, Blume-Peytavi U, Szab&oacute; EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/99\">",
"      Turjanmaa K, Reunala T. Isotretinoin treatment of rosacea. Acta Derm Venereol 1987; 67:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/100\">",
"      Taub AF. Treatment of rosacea with intense pulsed light. J Drugs Dermatol 2003; 2:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/101\">",
"      Lowe NJ, Behr KL, Fitzpatrick R, et al. Flash lamp pumped dye laser for rosacea-associated telangiectasia and erythema. J Dermatol Surg Oncol 1991; 17:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/102\">",
"      Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. J Eur Acad Dermatol Venereol 2009; 23:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/103\">",
"      Berg M, Edstr&ouml;m DW. Flashlamp pulsed dye laser (FPDL) did not cure papulopustular rosacea. Lasers Surg Med 2004; 34:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/104\">",
"      Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 2007; 21:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/105\">",
"      Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology 2005; 211:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/106\">",
"      Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol 2004; 15:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/107\">",
"      Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis 2001; 68:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/108\">",
"      Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol 2004; 137:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/109\">",
"      Barnhorst DA Jr, Foster JA, Chern KC, Meisler DM. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996; 103:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/110\">",
"      Kligman AM. Ocular rosacea. Current concepts and therapy. Arch Dermatol 1997; 133:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/111\">",
"      Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol 2009; 23:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/112\">",
"      Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/113\">",
"      Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol 2000; 42:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/114\">",
"      Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982; 6:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/115\">",
"      Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. Br J Dermatol 2009; 161:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/116\">",
"      Tahery J, Zakaria R, Natt RS. Diode laser treatment of rhinophyma. Clin Otolaryngol 2010; 35:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/117\">",
"      Apikian M, Goodman GJ, Roberts S. Management of mild to moderate rhinophyma with a 1,450-nm diode laser: report of five patients. Dermatol Surg 2007; 33:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/118\">",
"      Kempiak SJ, Lee PW, Pelle MT. Rhinophyma treated with cryosurgery. Dermatol Surg 2009; 35:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/119\">",
"      Sadick H, Goepel B, Bersch C, et al. Rhinophyma: diagnosis and treatment options for a disfiguring tumor of the nose. Ann Plast Surg 2008; 61:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/120\">",
"      Helm KF, Menz J, Gibson LE, Dicken CH. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol 1991; 25:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/121\">",
"      S&aacute;nchez JL, Berlingeri-Ramos AC, Due&ntilde;o DV. Granulomatous rosacea. Am J Dermatopathol 2008; 30:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/122\">",
"      Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol 1992; 9:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/123\">",
"      Khokhar O, Khachemoune A. A case of granulomatous rosacea: sorting granulomatous rosacea from other granulomatous diseases that affect the face. Dermatol Online J 2004; 10:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/124\">",
"      Schewach-Millet M, Shpiro D, Trau H. Granulomatous rosacea. J Am Acad Dermatol 1988; 18:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/125\">",
"      Smith KW. Perioral dermatitis with histopathologic features of granulomatous rosacea: successful treatment with isotretinoin. Cutis 1990; 46:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/126\">",
"      Krause MH, Torricelli R, K&uuml;ndig T, et al. [Dapsone in granulomatous rosacea]. Hautarzt 1997; 48:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/127\">",
"      Cunha PR, Rossi AB. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006; 86:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/128\">",
"      G&uuml;l U, G&ouml;n&uuml;l M, Kili&ccedil; A, et al. A case of granulomatous rosacea successfully treated with pimecrolimus cream. J Dermatolog Treat 2008; 19:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/129\">",
"      Lane JE, Khachemoune A. Use of intense pulsed light to treat refractory granulomatous rosacea. Dermatol Surg 2010; 36:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/130\">",
"      Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther 2006; 19:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/131\">",
"      Chamaillard M, Mortemousque B, Boralevi F, et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/132\">",
"      Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale. Cutis 2008; 81:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/133\">",
"      Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology 1994; 188:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/134\">",
"      Strauss JS. Rosacea fulminans. J Eur Acad Dermatol Venereol 2001; 15:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/135\">",
"      Ormond P, Rogers S. Case 3. Pyoderma faciale (PF) (rosacea fulminans). Clin Exp Dermatol 2003; 28:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/24/29066/abstract/136\">",
"      Bormann G, Gaber G, Fischer M, Marsch WC. Dapsone in rosacea fulminans. J Eur Acad Dermatol Venereol 2001; 15:465.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16632 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29066=[""].join("\n");
var outline_f28_24_29066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26656310\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2324120\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2324127\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2324134\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2324141\">",
"      Avoidance of flushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2324148\">",
"      Skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2324155\">",
"      Sun protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2324162\">",
"      Cosmetic camouflage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2324935\">",
"      ERYTHEMATOTELANGIECTATIC ROSACEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2324942\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2324949\">",
"      - First-line interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2324956\">",
"      - Second-line interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H696617\">",
"      Laser and intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H501291\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2325345\">",
"      PAPULOPUSTULAR ROSACEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2325353\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2325879\">",
"      - Mild to moderate disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2325366\">",
"      Topical metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2325386\">",
"      Topical azelaic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H16743134\">",
"      - Azelaic acid versus metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16742896\">",
"      Alternative topical agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2325624\">",
"      - Sulfacetamide-sulfur",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H25403012\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2325908\">",
"      - Moderate to severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2325871\">",
"      Oral tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H264219\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H689662\">",
"      - Combined with topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2326144\">",
"      Alternative oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H693879\">",
"      - Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H693795\">",
"      Oral isotretinoin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25403507\">",
"      - Laser and intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H689748\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H695717\">",
"      OCULAR ROSACEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H694796\">",
"      PHYMATOUS ROSACEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694836\">",
"      Early disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H694922\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H695009\">",
"      SPECIAL CASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695168\">",
"      Granulomatous rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695001\">",
"      Pediatric rosacea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695032\">",
"      Pyoderma faciale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26656310\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16632|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/34/22048\" title=\"figure 1\">",
"      Chromophore absorption spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16632|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/49/37649\" title=\"picture 1A\">",
"      Rosacea erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/61/32722\" title=\"picture 1B\">",
"      Rosacea erythema cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/52/41794\" title=\"picture 2A\">",
"      Rosacea papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/54/7011\" title=\"picture 2B\">",
"      Rosacea papules and pustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/514\" title=\"picture 3\">",
"      Rosacea rhinophyma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/3/15410\" title=\"picture 4A\">",
"      Rosacea papulopustular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/30/21989\" title=\"picture 4B\">",
"      Rosacea papules on face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/7/31869\" title=\"table 1\">",
"      Lasers in dermatology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12857?source=related_link\">",
"      Approach to flushing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_24_29067="Labs for fever in travelers";
var content_f28_24_29067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial laboratory evaluation for fever and tropical exposures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Routine laboratory tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count with differential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver enzyme and function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis (culture if abnormal sediment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid diagnostic test (if available) and blood smears for malaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other tests to consider (depends upon physical examination and exposure history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool culture and/or examination for blood, fecal leukocytes, ova and parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serologic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary antigens (eg, for Legionella)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood smears for Babesia, Borrelia, filaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow aspirate/biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biopsy of skin lesion, lymph nodes, other masses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination of cerebrospinal fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other imaging studies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29067=[""].join("\n");
var outline_f28_24_29067=null;
var title_f28_24_29068="First generation antipsychotic Rx poisoning - Rapid overview";
var content_f28_24_29068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    First generation antipsychotic medication poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rapid overview",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardinal feature of this overdose is CNS depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Most patients have mild tachycardia; occasional patients have additional features of the anticholinergic toxidrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute extrapyramidal syndromes (eg, acute dystonic reactions, akathisia) are uncommon in overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pupils may be any size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        QT prolongation is common but Torsade de Pointes (TdP) is rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No specific laboratory testing is required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain an ECG to evaluate for QT prolongation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rule out other causes of depressed mental status (eg, hypoglycemia, intracranial lesion) as clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rule out common coingestions (eg, aspirin, acetaminophen) and others as clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No specific antidote exists; treatment is supportive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute extrapyramidal syndromes can be treated with antimuscarinic medications (diphenhydramine or benztropine) or benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        For patients with significant QT prolongation:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Monitor the ECG until the QTc is &lt;500 msec and trending toward improvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Correct significant electrolyte abnormalities, particularly hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Avoid giving medications that further prolong the QT interval",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29068=[""].join("\n");
var outline_f28_24_29068=null;
var title_f28_24_29069="Drugs and toxins associated with pericardial disease";
var content_f28_24_29069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and toxins associated with pericardial disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drug-induced lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tocainide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydralazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methyldopa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Reserpine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydantoins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypersensitivity reaction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tryptophan",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cromolyn sodium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiosyncratic reaction or hypersensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methysergide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minoxidil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Practolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bromocriptine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psicofuranine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytarabine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptokinase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            p-Aminosalicylic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiazides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfa drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiouracils",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiosyncratic reaction or hypersensitivity (con't)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclyphosphamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclosporine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5-Fluorouracil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vaccines (Smallpox, Yellow fever)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            GM-CSF",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anthracycline derivatives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Doxorubicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Daunorubicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Serum sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign antisera (eg, antitetanus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blood products",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Venom",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scorpion fish sting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Foreign-substance reactions (direct pericardial application)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Talc (Mg silicate)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Silicones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline/other sclerosants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iron in &beta;-thalassemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asbestos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Secondary pericardial bleeding/hemopericardium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticoagulants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thrombolytic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Polymer fume fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhalation of the burning fumes of polytetrafluoroethylene (Teflon)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maisch, B, Seferovic, PM, Ristic, AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericaridal diseases of the European society of cardiology. Eur Heart J 2004; 25:587. Copyright &copy; 2004 European Society of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29069=[""].join("\n");
var outline_f28_24_29069=null;
var title_f28_24_29070="Candidal onychomycosis in a patient with CMCC";
var content_f28_24_29070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal onychomycosis in a patient with chronic mucocutaneous candidiasis (CMCC)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29070=[""].join("\n");
var outline_f28_24_29070=null;
var title_f28_24_29071="Chylous pericardial fluid";
var content_f28_24_29071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Milky chylous pericardial fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from Chan, RMT, Dodek. Arch Intern Med 1984; 144:1857.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_24_29071=[""].join("\n");
var outline_f28_24_29071=null;
